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        ABSTRACT 
INTEGRATION OF HSP90 INHIBITION IN COMBINATIONAL 
IMMUNOTHERAPIES TARGETING RECEPTOR TYROSINE KINASE EPHA2  
 
 
Limitations in CD8+ T cell recognition of tumor cells due to defects in their antigen processing 
machinery or the selection of variants expressing low or absent levels of cognate tumor antigens 
have been previously identified as impediments to effective cancer immunotherapy. Hence, 
treatment regimens that coordinately promote enhanced activation of anti-tumor CD8+ T cells, 
improved delivery of such effector cells into tumor sites, and augmented recognition of tumor or 
tumor-associated stromal cells by therapeutic CD8+ T cells, would be expected to yield greater 
clinical benefit. Using an MCA205 sarcoma model, I show that in vitro treatment of tumor cells 
with the HSP90 inhibitor 17-DMAG results in the transient (proteasome-dependent) degradation 
of the HSP90 client protein EphA2 and the subsequent increased recognition of tumor cells by 
Type-1 anti-EphA2 CD8+ T cells. In vivo administration of 17-DMAG to tumor-bearing mice 
led to: i.) slowed tumor growth; ii.) enhanced/prolonged recognition of tumor cells by anti-
EphA2 CD8+ T cells; iii.) reduced levels of myeloid-derived suppressor cells (MDSC) and 
regulatory T cells (Treg) in the tumor microenvironment (TME); and iv.) activation of tumor-
associated vascular endothelial cells in association with elevated levels of Type-1 tumor 
infiltrating lymphocytes (TIL). When combined with EphA2-specific active vaccination or the 
adoptive transfer of EphA2-specific CD8+ T cells, 17-DMAG cotreatment yielded a superior 
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CHAPTER 1.  INTRODUCTION 
Receptor tyrosine kinases (RTKs) are broadly over-expressed on the surface of tumor 
cells, effectively contributing to the metastatic and proliferative potential of these cells. 
While increased activation has been associated with carcinogenesis, it is also clear that 
decreased deactivation and subsequent reduced internalization of the receptor plays a role 
in tumor progression [1]. For this purpose, antibody agonists and inhibitors of small 
molecules designed to block signaling mediated by RTKs have been developed [2]. 
However, intervention by single agents has demonstrated modest efficacy, at best. A 
desirable setting from the immunological point of view would be to have reduced 
expression of RTKs on the tumor cell surface, while simultaneously increasing their 
presentation as a cognate antigen on MHC class I molecules. This would have a two-fold 
advantage of reducing oncogenicity as well as increasing immunogenicity. Thus 
immunotherapy combining increased presentation of RTKs along with administration of 
RTK-specific T cells would be a highly effective tool for anti-tumor therapy. HSP90 is a 
molecular chaperone protein that facilitates the sustained overexpression of its client 
proteins, including RTKs, in tumors [3,4]. Therefore, HSP90 inhibitors have gained 
increasing importance due to their ability to facilitate the selective degradation of RTKs. 
17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) is the newest 
generation geldanamycin analogue available, which has been tested to have reduced 
toxicity. It also has an added advantage of increased bioavailability, due to its water-
soluble nature [5,6]. Previous studies in our lab have looked at the effect of 17-DMAG on 
increasing RTK presentation on human tumor cells in vitro. These studies have shown 
that HSP90 inhibition in human tumor cells conditions them to be more effectively 
targeted by RTK-specific T cells [7].  In vivo studies involving 17-DMAG have focused 
on its toxicity and anti-tumor activity in mice, but no studies have looked at the potential 
of the drug to increase RTK presentation. Therefore, in order to assess the clinical 
significance of 17-DMAG treatment for enhancing anti-tumor immunotherapy with 
RTK-specific T cells, there was a need to recapitulate our studies in the mouse model. 
We hypothesized that increasing RTK presentation on mouse tumor cells in vivo by 17-
DMAG treatment will enhance anti-tumor immunotherapy. For our studies, we focused 
on EphA2, an RTK that is commonly over-expressed in most cancers, and plays an 
 2 
important role in their growth and metastasis [8]. We observed that in vitro treatment of 
tumor cells with the HSP90 inhibitor 17-DMAG results in the transient (proteasome-
dependent) degradation of the HSP90 client protein EphA2 and the subsequent increased 
recognition of tumor cells by Type-1 anti-EphA2 CD8+ T cells. In vivo administration of 
17-DMAG to tumor-bearing mice led to: i.) slowed tumor growth; ii.) 
enhanced/prolonged recognition of tumor cells by anti-EphA2 CD8+ T cells; iii.) reduced 
levels of myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) in the 
tumor microenvironment (TME); and iv.) activation of tumor-associated vascular 
endothelial cells in association with elevated levels of Type-1 tumor infiltrating 
lymphocytes (TIL). When combined with EphA2-specific active vaccination or the 
adoptive transfer of EphA2-specific CD8+ T cells, 17-DMAG cotreatment yielded a 
superior tumor therapeutic regimen that was capable of rendering animals free of disease. 
 We believe these studies will advance the use of 17-DMAG in concert with anti-EphA2 
immunotherapy in the clinical setting for cancer therapy.  
 
1.1. Receptor tyrosine kinases – function and life cycle 
 
Receptor tyrosine kinases (RTKs) are receptors for important growth factors and 
hormones. About 20 families of RTKs have been identified – and they include receptors 
of the EGFR, PDGFR and Eph family [9]. In a normal cell in steady state, RTKs mediate 
various signaling processes that play a role in cell growth, differentiation and survival 
[10]. Usually, ligand binding to an RTK leads to activation and dimerization of an RTK 
(either heterodimerization or homodimerization), and phosphorylation of tyrosine kinase 
residues in the cytoplasmic domain of the RTK [11-13]. Subsequently, phosphorylation 
sites act as docking sites for various signaling adaptor proteins like SH2, thus triggering 
binding of other signaling molecules and initiating an entire signaling cascade that 
mediate essential cell survival and growth processes [14]. Once signaling has been 
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initiated, RTKs are targeted for ubiquitination and the RTK-ligand complex is 
endocytosed in clathrin-coated vesicles [15]. After endocytosis, the RTK and the ligands 
are separated in sorting endosomes. Here, one of two scenarios may occur – i.)  the RTK 
and ligand may progress through the endocytic pathway into lysosomes and where they 
are degraded, thus ending the signaling reaction ii.) in another scenario, the RTK and 
ligand are separated into different vesicles in the sorting endosomes, and the ligand 
progresses for degradation in the lysosome, while the RTK is recycled and sent back to 
the cell surface where it can initiate another round of signaling [16]. Thus, in a normal 
cell, RTK signaling is a tightly regulated process. This process is defective in cancerous 
cells, mostly due to mutations in the phosphorylation sites (leading to a sustained state of 
phosphorylation/activation) or in the ubiquitin binding sites (preventing endocytosis of 
the active RTK), thus causing sustained expression and signaling through the RTKs, and 
leading to uncontrolled cell growth, differentiation and survival – thereby sustaining 
tumorigenesis [13,17-21].  
 
1.2. Receptor tyrosine kinase EphA2 
1.2.1. Eph Receptor and Ephrin Ligands 
 
The Eph family of receptors is comprised of 16 members, making it the largest known 
group of receptor tyrosine kinases (for nomenclature, refer to 
http://ephnomenclature.med.harvard.edu/cell_letter.html) [22]. They have been divided 
into classes- EphA and EphB, depending on sequence homology. Correspondingly, two 
classes of interacting ligands – ephrin-A and ephrin-B, have been defined. The EphA 
receptor family consists of 10 members (EphA1-10), and these have been observed to 
promiscuously bind 6 ephrin-A ligands (ephrinA1-ephrinA6). The EphB receptor family 
consists of 6 members (EphB1-EphB6) that bind ephrinB transmembrane ligands 
(ephrinB1-ephrinB3) [8,23]. However, dedicated binding of EphA and EphB receptors to 
ephrinA and ephrinB ligands, respectively, doesn’t seem to be a steadfast rule. As an 
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example, Ephrin-B molecules bind with low affinity to EphA4, whereas ephrin-A5 is 
known to interact with EphB2 [24-26]. 
 
1.2.2. Eph receptors and Ephrins – structure and life cycle 
 
Eph receptors are transmembrane glycoproteins with an extracellular domain (that plays a 
role in ligand binding) and a cytoplasmic domain that possesses tyrosine kinase activity. 
The extracellular domain is unique to the Eph receptor family and consists of a ligand 
binding globular domain, a cysteine-rich region and two fibronectin type III repeats that 
mediate receptor dimerization. The cytoplasmic domain consists of a transmembrane 
region with two autophosphorylation sites, a kinase domain, a PDZ-binding motif and a 












 Figure 1: Structure of Eph receptors (left) and Ephrin A and B ligands (right) 
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Binding of Eph receptors to their ligands leads to their homo/heterodimerization with 
another receptor-ligand complex to form tetrameric complexes, causing receptor 
activation and autophosphorylation. This initiates a series of signaling events that are 
specific for the receptor and the type of cells they are expressed in. Generally, Eph 
receptors and their ligands are expressed abundantly during fetal development and at 
lower levels in normal adult somatic tissues [8].  
 
Eph receptors were originally observed to be involved in a number of processes during 
embryonic development viz. neural crest cell migration, developing tissue boundaries and 
axon guidance and development [27-30]. Recently, however, they have also been 
implicated in adult tissues where signaling through the receptor modulates the 
attachment, shape and motility of the cells by affecting expression of integrins and 
adhesion molecules on the cell surface [31-38]. In addition, Eph receptors (especially 




The EphA2 gene is located on human chromosome 1, and encodes a 130 kDa, 976 amino 
acid Type-1 glycoprotein. EphA2 binds to ephrin-A1, -A3, -A4, -A5, but does not require 
ligand binding for its enzymatic activity [39]. Along with other Eph/ephrin family 
members, EphA2 is involved in the organization of the nervous system and vasculature 
during embryonic development, and has been observed to be expressed on a subset of 
stem cells as well [41-43]. In normal adult tissues, EphA2 is expressed at low levels on a 
broad range of epithelial tissues, where it is principally localized to sites of cell-to-cell 
contact, and may play a role in contact inhibition of cell growth/migration that is critical 
for the organization and formation of epithelial layers in EphA2+ tissues [44,45]. EphA2 
is also expressed by endothelial cells where it contributes to normal tissue (and tumor) 
neovascularization in the adult. In addition, EphA2 expression on Langerhans- and 
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interstitial-type dendritic cells (DC) has been reported, suggesting the possible role(s) of 
EphA2 in the localization and networking functions of Langerhans cells in the 
epithelium, as well as their ability to traffic and stimulate T cells under the appropriate 
activating conditions [46-48]. 
 
1.3.1. Regulation of EphA2 Expression 
1.3.1.1. EphA2 Expression and Life Cycle in Non-transformed Tissues 
 
In normal adult tissues, EphA2 is expressed at low levels on a diverse array of epithelial 
tissues, where it may stably bind to its ligand, ephrin-A1 present on the surface of 
neighboring cells [49,50]. In contrast, malignant cells express high levels of EphA2 
protein, but these molecules only poorly bind to relevant ligands [51]. The EphA2 gene is 
expressed most highly in tissues that contain a high proportion of epithelial cells (viz. 
skin, small intestine, and lung). However, lower expression levels have been detected in 
kidney, brain, and spleen. Very low EphA2 protein levels have been observed in heart, 
skeletal muscle, liver, testes, and thymus [44] .  
 
Upon ligand binding, EphA2 seems to follow a similar internalization/degradation 
pathway as seen with other RTKs (as described earlier). Using ephrinA1-Fc fusion 
protein or EphA2-specific agonistic antibody, it has been shown that once ligand binding 
takes place, the EphA2 receptor interacts with c-Cbl protein and gets targeted for 
degradation through the proteasome. Moreover, these studies suggest that cellular levels 
of EphA2 protein are regulated by various proteins (Cbl, PTPs, etc.)  and are dependent 
on ligand-based stimulation [52-55]. One interesting observation is that active EphA2 
may be found in a non-phosphorylated state. Therefore, in the absence of ligand binding 
signals, EphA2 exhibits constitutively active enzyme activity, and yet this does not 
appear to accelerate the turnover of EphA2 protein. Such deregulation may result in the 
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overexpression of the EphA2 protein and a progressive accumulation of EphA2 signal 
strength (supporting tumorigenesis) [52]. 
 
1.3.1.2. Genetic Regulation of EphA2 
 
EphA2 is generally present in low levels in adult tissues, while the levels increase 10-100 
fold in tumors. Therefore, a number of studies have focused on elucidating the 
mechanisms that regulate EphA2 expression in normal cells but not tumor cells. The 
murine EphA2 promoter contains binding sites for Hoxa1 and Hoxb1 homeobox 
transcription factors, which appear to upregulate EphA2 expression during brain 
development [53]. Induced expression of E-cadherin has also been observed to increase 
EphA2 expression. In addition, several members of the p53 family have also been 
observed to regulate EphA2 expression, and p53 has a binding site in the EphA2 
promoter region where it can bind in response to DNA damage [56].  
 
EphA2 transcription is also enhanced by Ras-Raf-MAPK kinase pathway activation. 
Transforming mammary epithelial cells by Ras overexpression also induced EphA2 
overexpression [38]. Raf activation has also been known to directly induce EphA2 
mRNA and protein expression [57]. In addition, various stimuli/stressors that invoke the 
Ras-Raf-MAPK signaling cascade are potent inducers of EphA2 expression e.g. 
Interleukin (IL)-1ß, IL-2, and EGF. Deoxycholic acid, a well-known constituent of bile 
acid and cancer promoter, upregulates EphA2 expression, at least partially via activation 
of the MAPK pathway [58,59]. In addition, systemic injection of lipopolysaccharide 
(LPS; a MAPK activator via TLR2/4 stimulation) increased EphA2 mRNA expression in 
the liver [60]. Thus, although a number of factors have been identified in EphA2 
regulation, further studies will be required to gain a comprehensive picture of EphA2 
gene regulation.  
 
 8 
1.3.2. Role of EphA2 in Cancer 
1.3.2.1. Overexpression of EphA2 in Cancer 
 
EphA2 overexpression has been reported in a variety of cancers, with differences being 
more pronounced in metastatic tumors versus non-invasive cancer cells. Metastatic 
prostate cancer cells express 10-100 times greater levels of EphA2 protein expression 
versus prostate epithelial cells [61]. Similar observations noted for malignant mammary 
tumor cells and pancreatic adenocarcinoma cells (when compared to benign mammary 
epithelial cells and non-invasive pancreatic cells respectively) [62,63]. Herrem et al. 
reported that EphA2 is expressed in metastatic RCC cell lines at levels significantly 
higher than primary RCC cell lines, an observation replicated in freshly resected clinical 
samples. In addition, we compared RCC and normal adjacent kidney (NAK) tissues and 
reported that higher levels of EphA2 were present in significantly advanced and more 
vascularized tumors [64]. 
 
Based on these reports, it could be argued that EphA2 protein levels can be used to 
predict prognosis and clinical outcome in patients with EphA2+ tumors.  To support this 
hypothesis, our group has shown that the degree of EphA2 overexpression by RCC 
tissues (versus normal autologous kidney tissue) is predictive of short-term (<1 year) 
versus longer-term (1 year or more) disease-free status, as well as, overall survival. Also, 
patients that had tumors with low EphA2 levels were more likely to remain disease-free 
for a longer period of time, while those with tumors expressing high levels of EphA2 
relapsed quickly and survived for shorter periods of time [64].  
 
1.3.2.2. Mechanisms of EphA2 Overexpression in Cancer 
Mechanisms by which EphA2 is consistently over-expressed in tumor cells have not been 
completely elucidated, and hence is the subject of much investigation. Possible 
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mechanisms could include EphA2 gene amplification, decreased rates of protein 
degradation, or a combination of both. Another reported mechanism proposes that miR-
26b may act as a tumor suppressor in glioma and it directly regulates EphA2 expression. 
EphA2 is a direct target of miR-26b, and the down-regulation of EphA2 mediated by 
miR-26b may be dependent on the binding of miR-26b to a specific response element of 
microRNA in the 3'UTR region of EphA2 mRNA [65]. An attractive hypothesis with 
EphA2 over-expression by tumor cells involves the disruption of EphA2 homeostatic 
protein degradation. For EphA2 to be properly degraded, it needs to get phosphorylated, 
and internalized. Any defect in this process may result in the accumulation of cell surface 
EphA2 molecules [38,51,66]. Of particular interest in this regard is LMW-PTP, a 
phosphatase which preferentially dephosphorylates pEphA2, and which is overexpressed 
in several form of cancer. Notably, overexpression of LMW-PTP by tumor cells is 
associated with decreased levels of tumor pEphA2, and enhanced levels of EphA2 on the 
tumor cell surface [66-68]. 
 
Additional/alternative mechanism(s) linked to elevated EphA2 expression may involve 
E-cadherin expression on tumors. E-cadherin is a major protein involved in cellular 
adhesion, and is localized in adherent junctions formed between adjoining cells in tissues, 
the same sites as which EphA2 is expressed on tumors. In order to mediate signaling, 
EphA2 needs to bind its corresponding ligand (i.e. ephrin-A1) on adjacent cells, and in 
the case of tumor cells, this ability appears to be affected due to unstable cell-cell contact 
[69,70]. Hess et al. reported that E-cadherin and EphA2 seem to be co-localized in cell 
adhesion junctions and that E-cadherin regulates EphA2 expression by modulating its 
ability to interact with, ephrinA1 [71]. Thus, E-cadherin serves as a regulator EphA2 
expression at the cell surface. In fact, an inverse correlation has been reported between E-
cadherin and EphA2 expression in bladder carcinoma [72]. 
 
Furthermore, as discussed earlier, deficiencies in p53 and estrogen receptor levels may 
contribute to tumor cell overexpression of EphA2. An analysis of ovarian cell lines and 
human ovarian cancers showed that EphA2 overexpression occurred in 91% of tumors 
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with p53 deficiency versus 68% in tumors with wild type p53, suggesting the possible 
role of p53 in EphA2 accumulation in cancer cells [73]. 
 
An interesting observation is that in normal cells, EphA2 is expressed at low levels, and 
is present in a tyrosine phosphorylated state at points of cell contact. However, in 
neoplastic epithelial cells, it is present abundantly in a non-tyrosine phosphorylated state, 
localized at the leading edge of the invasive cells [52,74]. There may be several reasons 
associated with this anomaly. EphA2 phosphorylation and localization is observed to be 
dependent on E-cadherin expression, and loss of E-cadherin expression and decrease in 
cell adhesion is a characteristic often displayed by neoplastic cells [38]. The explanation 
could also be low levels of EphrinA1 (leading to low EphA2 phosphorylation) or rapid 
action by protein tyrosine phosphatases (PTPs) like LMW-PTP that may rapidly associate 
with EphA2 immediately after receptor phosphorylation [67]. Either way, EphA2 is a 
unique RTK since its tyrosine kinase activity doesn’t seem to be entirely dependent on 
ligand binding and tyrosine residue phosphorylation. 
 
1.3.2.3. Role of EphA2 in Tumorigenesis 
 
A study performed by Zelinski et al., showed that overexpression of EphA2 (via 
transfection of specific cDNA) in mammary epithelial cells was sufficient to promote 
cellular transformation, allowing these cells to form invasive tumors/metastases in nude 
(athymic) mice [51]. EphA2 cDNA transduced cells exhibited defects in adhesion, 
subcellular distribution, and decreased EphA2 p-Tyr content, all of which are 
characteristics of metastatic breast cancer cells. The prominent difference observed in 
cells overexpressing EphA2 was the inability of transgenic EphA2 to interact with its 
natural ligand, ephrinA1. However, artificial stimulation of EphA2 with an agonistic 
antibody was able to reverse the growth and invasiveness of EphA2-transformed cells in 
this model [38].  
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In addition, enforced overexpression of the EphA2-associated PTP, LMW-PTP, was 
found to be sufficient to transform normal epithelial cells in vitro, with LMW-PTP acting 
as an inducer of tumor onset and progression in animal models [67]. This oncogenic 
potential associated with LMW-PTP, may be attributed to its ability to dephosphorylate 
EphA2, leading to EphA2 accumulation in tumors. This is consistent with the constantly 
activated and non-phosphorylated form of EphA2 that’s over-expressed in the tumor 
[51,54,66]. This form of EphA2 may be associated with poor cell adhesion, inhibition of 
MAPK pathway (important for cellular responses to growth factors), enhanced growth 
and metastatic potential of the tumors.  It may also be possible that cellular 
overexpression/ decreased phosphorylation of EphA2 results in an abnormal distribution 
of this RTK, disruption of cell-to-cell contacts, and an enhancement in cell-to-
extracellular matrix (ECM) attachment, giving rise to increased cell motility and 
metastasis [37,63,71].  However, further studies are needed to elucidate in further detail  
the underlying mechanisms of EphA2 in tumorigenesis. Pathways of EphA2-mediated 




        Figure 2: Proposed role of the EphA2/ephrinA1 system in solid tumor cells 
 
 
1.3.2.4. EphA2 in angiogenesis 
Apart from tumorigenesis, EphA2 and its interaction with EphrinA1 is also known to 
play an important role in angiogenesis and tumor neovascularization [75]. Ogawa et al. 
first reported the presence of EphA2 and ephrinA1 in blood vessels of breast cancer and 
Kaposi’s sarcoma tissues, and it was subsequently proved that ephrinA1 could stimulate 
EphA2 becomes overexpressed possibly due to increased gene expression or a lack of ephrinA1-
induced receptor down-regulation. Overexpressed EphA2 is nonphosphorylated and stimulates 
oncogenic processes. EphrinA1 causes receptor phosphorylation and subsequent down-
regulation, both of which likely contribute to the tumor-suppressing effects of the ligand in tumor 
cells. (−P), nonphosphorylated; (+P), phosphorylated. 
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EphA2-expressing endothelial cell migration and survival [76]. Several studies blocking 
EphA2 have demonstrated the demonstrated the disruption of angiogenesis in several 
tumor models as well as in other diseases, suggesting interaction between EphA2 in the 
endothelial cell with ephrinA1 in tumors or endothelial cells to mediate angiogenesis [77-
80]. In addition, EphA2-positive mouse breast cancer cells, when implanted into EphA2-
deficient mice, were deficient in tumor volume and failed to form solid tumors, thus 
underscoring the importance of EphA2 in tumor angiogenesis [81].  
 
While ephrin-A1 is expressed in both tumor and normal vascular endothelial cells, 
EphA2 appears to be differentially expressed by tumor-associated vascular endothelial 
cells [80]. Interestingly, EphA2 overexpression in both tumor cells and tumor-associated 
endothelial cells has been linked to increased vascularity/angiogenesis and poor clinical 
outcome in renal and ovarian carcinomas [82,83]. Thus, therapeutic agents designed to 
antagonize the expression/function of EphA2 have two potential clinically meaningful 
target cell types; EphA2+ tumor cells themselves and EphA2+ tumor-associated 
neovessels. 
 
1.4. Therapeutic Approaches Targeting EphA2 
1.4.1. Anti-EphA2 Antibodies 
 
Carles-Kinch et al. generated monoclonal antibodies to extracellular antibodies to EphA2 
and observed that a subset of antibodies induced EphA2 phosphorylation and 
internalization, followed by degradation, leading to reduced levels of EphA2 expression 
in tumor cell [54]. Interestingly, these antibodies recognized a distinct conformation of 
EphA2 specific for tumors, thus sparing normal EphA2-expressing blood vessels. These 
mAbs effectively inhibited tumor growth in human xenograft models, promoted 
increased tumor cell apoptosis, and decreased EphA2 protein levels in treated tumor 
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lesions [84,85]. Since these mAbs were specific for the tumor-specific form of EphA2, 
potential toxicity issues towards normal tissues could be excluded, thus providing 
significant clinical benefits to these therapeutic agents. In addition, combinational 
therapies implementing EphA2 agonistic antibodies and chemotherapeutic drugs (such as 
paclitaxel or tamoxifen) has helped overcome sensitivity of tumors to these drugs, thus 
increasing the anti-tumor efficacy, compared to groups receiving either therapeutic agent 
alone [86,87].   
 
1.4.2. Peptide Mimetics 
 
There have been reports defining 2 peptides that selectively bind the extracellular 
domains of EphA2 and prevent ephrin binding. These peptides serve as agonists and 
stimulate EphA2 phosphorylation and internalization, and have also been noted for 
agonist anti-EphA2 mAbs. When linked to exterior surfaces, these peptides target the 
delivery of phage particles to EphA2+ cells, suggesting potential therapeutic value in 
selectively delivering therapeutic agents into EphA2+ tumor sites [88]. 
 
1.4.3. Interventions Targeting EphA2 Ligands 
 
Soluble EphA2-Fc, a chimeric receptor of EphA2 fused with an IgG Fc fragment, inhibits 
signaling through the EphA2 receptor, and has been observed to inhibit VEGF-mediated 
and ephrin-A1-mediated angiogenesis [82]. Administration of soluble EphA2-Fc inhibits 
tumor angiogenesis, growth and even metastasis in vivo in murine tumor models. VEGF 
induces ephrin-A1 expression, which in turn activates EphA2-dependent angiogenesis. 
Hence, using this soluble EphA2-Fc would suppress tumor-associated VEGF-induced 
angiogenesis. With regard to safety concerns, no untoward toxicity on normal EphA2+ 
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tissues has been observed, while inhibition of angiogenesis was seen specifically in 
neoplastic tissues [77,78,80]. 
1.4.4. Gene Silencing by siRNA 
 
EphA2 gene silencing has recently gained interest as an attractive therapeutic approach to 
target EphA2 in tumors. Recent studies suggest that application of EphA2 siRNA 
suppresses EphA2 protein expression, tumor growth and inhibits metastasis in vivo via 
the induction of tumor cell apoptosis [89-91]. 
 
1.4.5. EphA2-based Vaccines 
 
Several immunogenic EphA2 peptides have been identified by our group and by Alves et 
al. These peptides are recognized by CD8+ or CD4+ T cells generated from normal 
donors or cancer patients, and by CD8+ T cells developed in HLA-A*0201-transgenic 
HHD mice [92,93]. In all cases, T cell lines and clones produced using EphA2 peptides 
as a stimulus also recognized EphA2+, HLA-matched tumor cell lines, including RCC. 
This supports the natural processing and MHC presentation of these epitopes on the 
tumor cells, allowing for effector T cell reactivity. Such EphA2-specific T cells have 
been identified in the peripheral blood of patients with RCC, prostate cancer or glioma, 
suggesting that these responses may be naturally primed during cancer progression 
[92,94,95].  
 
Therapeutic/protective EphA2+ cancer vaccines need to stimulate, polarize (i.e. Type-1) 
and protect anti-EphA2 T cells against the tumor. In this regard, active vaccination 
against EphA2, in order to elicit and sustain specific T cells would be anticipated to 
provide clinical benefit in EphA2+ cancer patients. Indeed, Hatano et al. demonstrated 
that DC pulsed with murine EphA2 peptide epitopes effectively elicit specific CTL 
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responses in vivo that are capable of inhibiting syngeneic tumor progression in C57BL/6 
mice in an EphA2+ as well as an EphA2- tumor models. While there remains a 
theoretical concern that vaccination with EphA2-derived peptides may induce pathologic 
autoimmune reactions in normal EphA2+ tissues (i.e. lung, spleen, kidney and liver), 
these organs were not infiltrated by T cells, nor was tissue pathology observed in 
vaccinated animals [96]. This may reflect greater densities of EphA2 epitopes presented 
on the surface of tumor cells versus normal tissues, with T cells exhibiting moderate 
avidity able to functionally respond to tumor cells. Under such conditions, while flirting 
with potential autoimmune toxicities that warrant further scrutiny, this type of vaccine 
may ultimately prove both safe and clinical effective. 
1.4.6. Other therapeutic approaches  
 
Like EphA2-Fc, Ephrin-A1 Fc is a dimerized version of ephrin-A1 fused to human 
immunoglobulin G (IgG) Fc. In vitro experiments suggest that EphA2 ligation by ephrin 
A1-Fc results in EphA2 phosphorylation, and consequent degradation of this RTK in 
concert with reduced tumor growth [63,97]. To investigate the impact of sustained 
ephrin-A1 delivery on tumor cells in vivo, adenoviruses encoding secreted forms of 
ephrin-A1 Fc have also been investigated. Noblitt et al. showed that adenoviral delivery 
of ephrin-A1 Fc (i.e. rAd.ephrin-A1) into breast cancer cells increases the degree of 
EphA2 activation and degradation, along with inhibited tumor growth in vitro. 
Furthermore, they demonstrated that intra-tumoral injection of rAd.ephrin-A1 limited 
human tumor growth in xenograft models [98,99]. With regard to their potential clinical 
utility, one concern in using ephrin-A1 Fc (protein or gene constructs) as a therapeutic 
agent is the fact that ephrin-A1 serves as a ligand for multiple Eph receptors (i.e. EphA4, 
EphA5, EphA6 and EphA7 in addition to EphA2), which may increase chances of 
unanticipated toxicities. While no gross toxicities were noted in the reported xenograft 




In addition to targeting the EphA2 gene, one may consider targeting PTPs linked to 
EphA2 expression/function, i.e. LMW-PTP, SHP2. By reducing the overexpressed levels 
of these PTPs in tumor cells, one might anticipate the normalization of pEphA2 levels 
and consequent EphA2 protein degradation. Our own data demonstrated that LMW-PTP 
silencing with siRNA reduced EphA2 protein expression of metastatic RCC cells, 
suggesting the possibility for an alternative therapeutic method (Wesa et al, unpublished 
data). 
 
1.5. MHC class I antigen presentation pathway 
 
Cell-surface-expressed MHC class I molecules present antigenic peptides on the cell 
surface so that they can be specifically recognized by cytotoxic T lymphocytes (CTLs). 
The generation of these peptides requires the degradation of proteins into peptide 
fragments of precise size. The protease responsible for the degradation of 
polyubiquitylated proteins is the 26S proteasome, which is composed of the 20S 
proteasome, representing the catalytic core, and two 19S regulator complexes that 
regulate the binding and unfolding of ubiquitylated substrates. The hydrolysing activities 
of the 20S core are conferred by three of the seven β subunits located in both of the inner 
heptameric β-rings, whereas the 19S regulator complexes (composed of six ATPase 
subunits and 9–10 non-ATPase subunits) attach to the outer heptameric α rings of the 20S 
core [100,101].  A constant supply of functional Hsp90 is needed to maintain the tertiary 
structure of the proteasome [102,103]. 
Although attachment of ubiquitin to proteins (ubiquitination) was initially identified as a 
signal that leads to proteasome degradation of the target protein, it has since become clear 
that attachment of ubiquitin can lead to different outcomes depending on the type of this 
attachment. All lysine residues of the ubiquitin molecules can be used for isopeptide bond 
formation. In addition, the pattern of post-translational modification dictates the fate of 
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the modified protein.  Diversification is conferred by whether one ubiquitin molecule or a 
chain of ubiquitins is attached. 
Mono-ubiquitination is a signal involved in receptor endocytosis and lysosomal sorting. 
Many receptor tyrosine kinases (RTKs) undergo ligand-induced mono-ubiquitination. As 
mentioned in section 1.1, process ligand-induced phosphorylation of the receptor gives 
the signal for receptor ubiquitination. E3 ligase cbl facilitates receptor ubiquitination and 
is the major E3 ligase for this purpose. Ubiquitinated receptors interact with ubiquitin-
binding proteins of the endocytic pathway and are escorted through clathrin-coated pits to 
clathrin-coated vesicles, endosomes and finally lysosomes. Mono-ubiquitination in 
multiple receptor sites (multiple mono-ubiquitination) has also been found to play a role 
in receptor endocytosis. Cbl E3 ligase also mediates multiple mono-ubiquitination. 
Multiple mono-ubiquitination is believed to stabilize interaction of receptors with 
ubiquitin receptors in order to enhance their transfer to lysosomes. Some ubiquitin 
receptors may also recognize only multi-ubiquitinated RTKs through multiple domain 
interactions ([104]). 
A chain of at least four ubiquitin molecules linked through lysine 48 is the signal for 
recognition of a target protein by the proteasome complex in order to be degraded 
([105]). Proteasome degradation after lysine 63 poly-ubiquitination has been described in 
to occur sometimes ([106]), but most often, lysine 63 poly-ubiquitination leads to 
proteolysis through autophagy-associated mechanisms ([107]). 
Major histocompatibility complex (MHC) class I molecules are constitutively expressed 
by virtually all somatic cells and they present peptides of 8 to approximately 12 amino 
acids in length to CD8+ T cells. Essential components for the formation of peptide-MHC 
class I complex (pMHC) are called as MHC class I antigen-presenting machinery (APM), 
including the proteasome, ERP1/ERAAP, transporter associated with antigen 
presentation complex (TAP, heterodimer of TAP1 and TAP2), general ER chaperones 
and tapasin [108,109]. There are two distinct pathways for presentation of peptides on 








In the direct presentation pathway, endogenous proteins are degraded by the 
proteasome into peptides within the cell cytosol, which are then transported by the 
TAP complex into the endoplasmic reticulum (ER) for loading into newly synthesized 
MHC class I molecules. Fully assembled (mature) class I molecular complexes 
(consisting of the MHC class I heavy chain, non-covalently bound β2-microglobulin 
and peptide) are then transported through the Golgi to the cell surface. In the cross-
presentation pathway, exogenous antigens are first phagocytosed, endocytosed (via 
specific or scavenger-type receptors), pinocytosed, or macropinocytosed by APC. 
During the formation of the phagocytic cup, the ER may fuse with the nascent 
phagosome to form early phagosomes that contain ER proteins, including all the 
components required for MHC class I antigen presentation (e.g. TAP, MHC-I), 
ubiquitin-conjugating enzymes and the translocon. Subsequently, internalized antigens 
in early phagosomes may transferred to the cytosol for degradation through the 
proteasome by as yet less understood mechanisms (blue ?) or remain in the 
phagosome, whereas antigenic peptides generated by proteolysis in these 
compartments may be loaded into nascent/recycled MHC class I complexes that are 
transported to the cell surface. 
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Most somatic cells have the capacity to present endogenous peptides in the context of 
MHC class I molecules. Endogenous proteins are degraded by the proteasome into 
peptides in the cytosol, which may then be transported by the TAP complex into the 
endoplasmic reticulum (ER) for loading into newly synthesized MHC class I molecules. 
Peptides may be trimmed by an ER-associated aminopeptidase (ERAAP or ERAP1) to a 
preferred loading length of 8–10 amino acids. Essential molecules for optimal peptide 
loading into MHC class I complexes include TAP, tapasin, calreticulin and ERp57. Fully-
assembled class I molecules are then transported through the Golgi to the cell surface 
[110-112]. 
 
The degradation mechanism of newly-synthesized and mis-folded proteins (known as the 
ER-associated degradation (ERAD) pathway), is currently under intense investigation as 
a major conduit through which endogenous proteins may be delivered back into the 
cytosol to serve as a source of MHC-presented peptides. The current ERAD paradigm 
suggests that proteins that fail to achieve their native conformations may be 
ubiquitinylated and retrotranslocated from the ER back into to the cytoplasm, where they 
face degradation by the proteasome after retro-translocation mediated via proteins such as  
Sec61 [109,113]. 
 
This retrotranslocation pathway has also recently been reported to play a role in the 
ability of DC to cross-present antigenic peptides to responder CD8+ T cells [114,115]. 
Exogenous antigens are first internalized by a variety of mechanisms (phagocytosed, 
endocytosed (via specific or scavenger-type receptors), pinocytosed, or 
macropinocytosed) by APC. From here the antigens are transferred to the cytosol by the 
translocon, ubiquitinated and processed by the proteasome, in a mechanism resembling 
ERAD. The degraded peptides are then transported to the ER by TAP and loaded into 




Both the direct- and cross-presentation pathways rely on the cleavage of polypeptides by 
the proteasome [116-118]. The subunit composition of the constitutive proteasome varies 
in different tissues [119]. In addition to the constitutive proteasome, professional APCs 
and most cells exposed to IFNγ express the immunoproteasome, which contains three 
different catalytic domains. Due to this change in multicatalytic specificity (versus the 
conventional proteasome), immunoproteasomes exhibit an altered cleavage site 
preference as well as a different cleavage rate. The immunoproteasome generally favors 
the production of MHC-binding peptides [120-122], Figure 3.  
 
To initiate a protective CTL response toward tumors, the antigens derived from tumor 
cells must be processed and presented by professional antigen presenting cells (APC) in 
the context of MHC class I molecules via cross-presentation pathway, since tumor cells 
are generally considered to be poor APCs due to defects in MHC molecule expression 
and/or a skewed balance towards co-inhibitory over co-stimulator molecule expression. 
On the other hand, to exert effector function, tumor specific CTLs need to recognize 
tumor cells in the form of (endogenously synthesized) tumor peptides presented by MHC 
class I through the direct presentation pathway [123]. 
 
1.6. Approaches to Increase RTK-derived Epitope Presentation in Tumor Cell MHC 
Class I Complexes 
 
Our lab has been interested in the identification of treatment strategies that allow for 
biased improvement in tumor cell (MHC class I) presentation of RTK-derived peptide 
epitopes, leading to the evaluation of RTKs agonists, PTP inhibitors and HSP90 
inhibitors. The first 2 modalities manipulate RTK internalization and subsequent 
proteasomal degradation, while the 3rd modality is based on the prevention of RTK 
folding/maturation by inhibiting chaperone function, leading to the re-routing of such 
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mis-folded proteins into the proteasome pathway as a clearance mechanism. In all cases, 
the derivative proteasome-generated peptides may serve as an enriched source of epitopes 
for MHC class I presentation to CD8+ T cells [7,124]. 
1.6.1. RTK Agonists and PTP Inhibition 
 
As described earlier, upon ligand binding, RTKs may become phosphorylated, 
ubiquitinated and internalized within “sorting” endosomes. Ubiquitinated RTKs are 
subsequently targeted towards a lysosomal compartment for proteolytic degradation, 
while dephosphorylated and/or non-ubiquitinated receptors may be recycled to the cell 
surface. Recent studies, however, demonstrate that polyubiquitinated RTK may also be 
delivered to the proteasome for degradation [125].  
 
In this context, reagents that promote RTK activation/internalization in tumor cells have 
the potential to facilitate the degradation of RTKs by enhancing (the normal life cycle of) 
RTK destruction by the proteasome. The net impact would be expected to be a 
conditional enhancement of RTK-derived peptide presentation within MHC class I 
complexes (i.e. by selectively driving RTK processing via the proteasome, the stochastic 
level of a given RTK peptide would be increased versus peptide derived from alternate 
source proteins) and improved recognition by low-moderate avidity anti-RTK CD8+ T 
cells. For example, RTK agonists (antibodies or ligand-Fc fusion protein) or PTP 
inhibitors would fall into this category and promote RTK internalization through direct 
activation of RTK or through inhibition of RTK dephosphorylation, respectively. 
Consequent proteasome activity could render treated tumor cells more sensitive to anti-
RTK specific T cells. Indeed, recent studies have reported that anti-Her2/neu antibody 
(Herceptin) treatment of Her2/neu+ tumor cells promotes enhanced sensitivity to 
Her2/neu-specific CTLs in vitro [126-128].  
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1.6.2. HSP90 Inhibition 
 
A rational approach to increase the proteasomal degradation of tumor cell-expressed 
RTKs would be through the inhibition of heat shock protein (HSP)90, a chaperone 
required in the decision of whether a misfolded “client” protein is recycled or degraded in 
cells. HSP90 is a constitutively expressed molecule that directs the normal folding and 
proteolytic turnover of its client proteins. HSP90 has an ever-expanding list of client 
proteins (see http://www.picard.ch/downloads/HSP90interactors.pdf), and various 
oncoproteins (including overexpressed RTKs) are a part of the list [4,129-131]. 
Furthermore, HSP90 is overexpressed manifold by tumor cells and may play a role in 
mediation of stabilization/ proper folding of mutant/mis-folded client proteins, thus 
permitting tumor cells to better endure imbalanced signaling pathways [4,132-134]. In 
fact, HSP90 has been deemed central to the ‘Six Hallmarks of Cancer’ i.e. six 
characteristics possessed by a cell to turn tumorigenic [3]. Therefore we hypothesized 
that when HSP90 function is inhibited, overexpressed and misfolded proteins would be 






Figure 4: A paradigm for using HSP90 inhibitors to increase tumor and stromal cell 
presentation of RTK-derived peptides 
 
1.6.3. HSP90 
1.6.3.1. HSP90 structure 
 
The HSP90 is a constitutively expressed cellular protein that constitutes 1–2% of the total 
protein load [135,136]. Five HSP90 isoforms have been identified to date, including 
Overexpression of WT/mutated RTKs by cells in the tumor microenvironment occurs 
in part due to the stabilizing influence of the HSP90 chaperone complex. 
Pharmacologic inhibition of HSP90 leads to the inability to salvage mis/un-folded 
RTKs, leading to their proteasome-dependent processing, TAP-transport and loading 
into, and presentation by MHC class I molecules expressed on the cell surface.  
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cytoplasmic HSP90α- and β-isoforms, endoplasmic reticulum localized glucose regulated 
protein 94 (GRP94), mitochondrial tumor necrosis factor receptor-associated protein 1 
(TRAP1) and membrane-associated HSP90N [137]. It is a flexible homodimer where the 
monomers consist of three domain -- an N-terminal, ATP-binding domain, a middle (M), 
ATP-hydrolysis-regulating domain and a C-terminal dimerization domain [138-140]. The 
C-terminus also regulates ATPase activity and recruits co-chaperones through a 
conserved EEVD motif). Co-chaperones, such as HOP, CDC37, p23, Aha1 and PPIase, 
play an important role in client protein maturation and modulation of ATPase activity. 
Co-chaperones also recruit specific client proteins to HSP90 and/or stabilize HSP90 in an 
ATP-bound state to prolong the half-life of the mature multi-chaperone complex [141]. 
Adenosine triphosphate hydrolysis alters HSP90 structure and promotes its chaperone 
function. Therefore, in cells, HSP90 generally exists in 2 conformations – an active 
“open” conformation that is an ATP bound state during client protein binding, and an 
inactive “closed” conformation [142].  
 
1.6.3.2. HSP90 mechanism of action 
The HSP90 protein contains three functional domains, the ATP-binding, protein-binding, 
and dimerizing domain, each of which play a crucial role in the function of the protein. 
ATP binding 
The region of the protein near the N-terminus has a high-affinity ATP-binding site. The 
ATP binds to a sizable cleft in the side of HSP90 protein, that has a high affinity for ATP, 
and in the presence of a suitable protein substrate, HSP90 hydrolyzes ATP. Direct 
inhibitors of ATP binding or allosteric inhibitors of either ATP binding or ATPase 
activity can block HSP90 function [143].  Another interesting feature of the ATP-binding 
region of HSP90 is that it has a “lid” that is open during the ADP-bound state and closed 
in the ATP-bound state. In the open conformation, the lid has no intraprotein interaction, 
and when closed comes into contact with several residues [131]. The ATPase-binding 
region of HSP90 is currently under intense study, because it is the principal binding site 
of HSP90-inhibiting drugs [144]. 
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Protein binding 
The protein-binding region of HSP90 is located toward the C-terminus of the amino 
sequence. As mentioned earlier, the HSP90 protein can adopt two major conformational 
states. The first is an open ATP-bound state and the second is a closed ADP-bound state. 
Thus, ATP hydrolysis drives what is commonly referred to as a “pincer-type” 
conformational change in the protein binding site [145]. 
HSP90, while in the open conformation, leaves some hydrophobic residues exposed, to 
which unfolded and misfolded proteins that have unusual hydrophobic regions exposed 
may be recruited with high affinity [146]. When a bound substrate is in place, ATP 
hydrolysis by the ATPase located near the N-terminus of the HSP90 protein forces 
conformational changes that ensnares the client protein [147]. The ability of HSP90 to 
physically “capture” proteins allows it perform several functions including assisting 
folding, preventing aggregation, and facilitating transport. 
 
1.6.3.3. HSP90 function in normal cells  
 
HSP90 is one of the most abundant molecular chaperones that regulate folding, 
maturation and stabilization of proteins. HSP90 interacts with a set of proteins, called 
client proteins (see http://www.picard.ch/downloads/HSP90interactors.pdf) [148]. In 
unstressed cells, HSP90 plays a number of important roles, which include assisting 
folding, intracellular transport, maintenance, and degradation of proteins as well as 
facilitating cell signaling [102,103,149]. 
 
HSP90 is known to associate with the non-native structures of many proteins, which has 
led to the proposal that HSP90 is involved in protein (re)folding in general. In addition, 
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eukaryotic proteins that are no longer needed or are misfolded / damaged are usually 
marked for destruction by the polyubiquitation pathway. These ubiquitinated proteins are 
recognized and degraded by the 26S proteasome. Hence the 26S proteasome is an integral 
part of the cell's mechanism to degrade proteins. Furthermore a constant supply of 
functional HSP90 needed to maintain the tertiary structure of the proteasome 
[102,103,149]. A lesser studied function of HSP90 is its role in signaling. The 
glucocorticoid receptor (GR) is the most thoroughly studied example of a steroid receptor 
whose function is crucially dependent on interactions with HSP90 [150]. In the absence 
of the steroid hormone cortisol, GR resides in the cytosol complexed with several 
chaperone proteins including HSP90. These chaperones maintain the GR in a state 
capable of binding hormone [151,152]. Another role of HSP90 is to bind immunophilins 
(e.g., FKBP52) that attach the GR complex to the dynein protein trafficking pathway, 
which translocates the activated receptor from the cytoplasm into the nucleus. Once in the 
nucleus, the GR dimerizes and binds to specific sequences of DNA and thereby 
upregulates the expression of GR responsive genes [151,152]. HSP90 is also required for 
the proper functioning of several other steroid receptors, including those responsible for 
the binding of androgen, estrogen, and progesterone [153-156].  In addition, Udono et al. 
demonstrated that HSP90 facilitates MHC class I antigen processing through epitope 
production in a complex of the 26 S proteasome, with inhibition of HSP90 in vivo using 
geldanamycin partially disrupting the 26 S proteasome structure, limiting the efficiency 
of MHC class I biosynthesis, leading to down-regulated MHC class I expression ([157]).  
 
1.6.3.4. HSP90 function in tumors/ tumorigenesis 
 
Cancerous cells over express a number of proteins, including growth factor receptors, 
such as VEGFR and EGFR [158,159], or signal transduction proteins such as PI3K and 
AKT. HSP90 plays a role in folding and stabilization of these proteins in the tumors. In 
addition, HSP90 also stabilizes mutant proteins such as v-Src, the fusion oncogene 
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Bcr/Abl, and mutant forms of p53 that appear during cell transformation. HSP90 is also 
required for induction of vascular endothelial growth factor (VEGF) and nitric oxide 
synthase (NOS) [160]. Both are important for de novo angiogenesis that is required for 
tumor growth. It also promotes metastasis by assisting the matrix metalloproteinase 
MMP2, which modulates cell adhesion and promotes cell migration. Thus, HSP90 plays 
a role in stabilizing tumor overexpressed client proteins, many of which serve to foster 
tumor growth and dissemination. HSP90-mediated “life support” for tumors also allows 
these cells to better tolerate genetic instability based on the accumulation of client 
proteins associated with DNA repair [161,162].  
HSP90 plays multiple roles in the cell, where it is essential for the creation, maintenance, 
and destruction of proteins. Its normal function is critical to maintaining the health of 
cells, whereas its deregulation may contribute to carcinogenesis. Indeed in tumors, most 
HSP90 clients are overexpressed and the stability provided by HSP90 helps mediate 
acquisition and maintenance of the properties necessary for transformation of a normal 
cell into a cancer cell; ability to evade apoptosis, ability to be self-sufficient for growth, 
ability to invade surrounding tissue and to metastasize to distant sites, ability to undergo 
limitless replication, ability to promote neoangiogenesis, and ability to ignore antigrowth 
signals. Therefore, the use of HSP90 inhibitors in cancer treatment highlights HSP90's 
importance as a therapeutic target. [3,4,161,163]  
1.6.4. HSP90 Inhibitors 
 
Many chemicals have been developed to inhibit HSP90 function. These can be 
categorized into two groups depending on the sites of the HSP90 molecule that are 
targeted; 1) those impacting the N-terminal ATP/ADP pocket of HSP90 and 2) those 
affecting the C-terminal domain of HSP90 [4,164]. 
 
The concept of HSP90 inhibition was greeted with much initial skepticism because of the 
severe toxicity issues involved in targeting a ubiquitous housekeeping protein. This 
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misperception has since been dismissed and HSP90 inhibitors are one of the most 
actively studied pharmacologic agents, with 17 of them having entered clinical trials 
[165]. So far, impressive clinical activity has been achieved with several HSP90 
inhibitors in multiple tumor types, showing great promise for these inhibitors as 
therapeutic agents [166].  
 
1.6.4.1. Geldanamycin and its derivatives 
 
Initially, researchers established the ability to target HSP90 using the natural products 
radicicol and geldanamycin. These products were isolated in 1953 and 1970, but their 
ability to interact with HSP90 was only determined years later [167]. Another 
breakthrough was the discovery that geldanamycin and radicicol mimic the relatively 
unusual structure that ATP adopts in the deep, N-terminal, nucleotide-binding pocket of 
HSP90, thereby leading to potent and selective inhibition of ATP binding and hydrolysis 
[168], and thus leading to depletion of the oncogenic client proteins and mediating their 
proteasomal degradation [169,170].  
 
Geldanamycin and radicicol have provided invaluable insights on HSP90 structure, 
function and its value as an anti-cancer target. Although geldanamycin and radicicol 
proved too toxic and unstable/reactive for clinical use, they each provided the chemical 
basis for subsequent drugs that entered the clinic [171]. The first HSP90 inhibitor to 
progress to clinical trials was the better-tolerated geldanamycin analog 17-allylamino-17-
demethoxygeldanamycin (17-AAG, KOS-953, tanespimycin). In phase I studies with 17-
AAG, researchers successfully demonstrated HSP90 inhibition using a validated 
pharmacodynamic biomarker signature of client protein depletion and HSF1-dependent 
HSP70 induction [172,173]. 17-AAG also showed impressive results in clinical trials in 
phase I and II studies in HER2+, trastuzumab-refractory breast cancer where objective 
Response Evaluation Criteria in Solid Tumors (RECIST) responses were seen on a 
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weekly schedule of 450 mg/m2 [174,175].  Both GA and 17-AAG have also been 
observed to affect other HSP90 isoforms like gp96 (Grp94) ([176]).  
 
Although prolonged disease stabilization was achieved in phase I studies of 17-AAG in 
various tumor types, no complete or partial tumor responses were seen [177]. This 
limited activity could be due to suboptimal inhibition of the target client proteins, most 
likely due to insufficient drug dose or frequency of administration. Consistent with the 
clinical data, animal model studies in relevant tumors (e.g., ovarian, colon, breast and 
melanoma) show a similar pattern of growth inhibition or cytostatic arrest rather than 
tumor regression in response to 17-AAG alone [159,173,177-180]. Another (major) 
limitation of 17-AAG was its requirement to be dissolved in DMSO, which significantly 
increased the toxicity of the drug and had a dose-limiting effect, which ultimately 




Another geldanamycin analog, alvespimycin (17-dimethylaminoethylamino-17-
demethoxygeldanamycin, 17-DMAG) has improved formulation and pharmacokinetic 
properties. The biggest advantage that 17-DMAG offers over its predecessors is its ability 
to be dissolved in water, and hence it can be given orally making it highly bioavailable. 
Egorin et al looked at the pharmacokinetics and tissue distribution of 17-DMAG in 
CDF21 mice and Fischer rats and observed that a dose as high as 75 mg/Kg did not seem 
to cause any discernible weight loss or other toxicity symptoms. In addition, they 
observed that giving the drug orally and i.v. provided more bioavailability than i.p. 
administration [5]. In a study comparing 17-AAG with 17-DMAG on 64 different tumor 
cell lines, 17-DMAG was found to be more effective at inducing tumor apoptosis and 
inhibiting tumor cell proliferation when compared to 17-AAG. In addition, a lower dose 
of 17-DMAG was required to induce these effects versus 17-AAG [182]. These 
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observations were also replicated in vivo in a number of tumor models viz. breast cancer, 
cervical cancer and ovarian cancer [6,183].  
Phase I studies of 17-DMAG have recently concluded, where the drug was found to be 
well-tolerated and effective. In a study carried out on patients with advanced cancer, a 
dose of 21mg/m2/d given i.v. twice weekly, was observed to be well-tolerated with minor 
side-effects like nausea and low grade fever. About half the patients had stable disease. 
Similar finding were observed in a phase I clinical trial involving advanced acute 
myeloid leukemia patients [184]. More recently, studies by Ramanathan et al. and Pacey 
et al. have concluded that a 17-DMAG dose of 80mg/m2 (either given as a single bolus 
or a staggered dose) once a week for 3 weeks was well tolerated by patients with 
advanced tumors. They observed complete remission in patients with prostate cancer, 
partial response in melanoma patients while patients with sarcomas and renal cell 
carcinoma had stable disease [185-187]. Thus, in spite of encouraging results observed in 
Phase I trials, it is evident that a safe dose of 17-DMAG is insufficient to mediate 
complete tumor regression in patients. Therefore, a safe and effective combination 
therapy involving 17-DMAG could represent a superior anti-tumor therapeutic approach.  
 
1.6.4.3. 17-DMAG combinational studies 
 
17-DMAG has been used in combination with chemotherapy or irradiation to improve 
anti-tumor efficacy of either modality. Combination of 17-DMAG with irradiation has 
been used in a number of tumors in vitro as well as in vivo. 17-DMAG caused abrogation 
of the G2 and S phase of the cell cycle and interference in DNA damage response in 
tumor cells [182,188,189]. Ultimately, combination of 17-DMAG with irradiation have 
significantly higher anti-tumor efficacy compared to either modality in a number of 
tumors including lung and breast cancers in vitro as well as in vivo [182,189]. 
Combination of 17-DMAG with chemotherapy has been evaluated mostly in non-solid 
tumors. Studies combining 17-DMAG with an AKT inhibitor in multiple myeloma (MM) 
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showed increased susceptibility of MM cells to apoptosis and cell cycle arrest. This 
combination also induced apoptosis of endothelial cells and inhibited angiogenesis in 
vitro [190]. In mantle cell lymphoma, combination of 17-DMAG with a histone-
deacetylase inhibitor Vorinostat induced cell cycle arrest in disparate cell cycle phases, 
and increased apoptosis of tumor cells was seen in combination therapy cohorts [191]. 
Apart from increasing anti-tumor efficacy of single-modality treatments, 17-DMAG has 
also been observed to complement other therapies when they fall short. For example, p53 
mutation causes resistance to apoptosis by single chemotherapeutic agents like 
doxorubicin. However, addition of 17-DMAG to the therapeutic regiment overcame this 
resistance [192]. Similarly, 17-DMAG was able to help overcome cisplatin resistance 
observed in treated bladder cancer cells [193]. However, 17-DMAG combination studies 
have been limited to in vitro studies mostly, and advanced in vivo and clinical studies 
need to be carried out to further evaluate the net therapeutic value of these combinational 
approaches.  
The induction of the heat shock response appears to be an unfortunate drawback of all the 
N-domain inhibitors of HSP90, including the newer purine and 4,5-diaryisoxazole 
resorcinol compounds [194-196]. However it would appear that it can be avoided by 
switching to a recently-developed class of HSP90 inhibitor that binds with high-affinity 
to the C-terminal region of the chaperone. One of these C-terminal inhibitors, KU135, 
has been shown to promote client degradation, but not Heat shock factor (HSF)-1 
induction, and to act as a potent inducer of mitochondria-mediated apoptosis [197]. 
Alternatively, it should be possible to overcome the detrimental effects of N-domain 
inhibitors inducing HSF-1 by using these inhibitors in combination with other drugs. In 
this respect inhibitors of the HSP70 family of molecular chaperones are potentially of 
tremendous potential. The status of HSP70 drug development has recently been reviewed 
[198,199], the targeting of HSP72 by one such compound enhancing HSP90 inhibitor-
induced apoptosis in myeloma cells [200]. In cell culture the combinatorial use of 17-
AAG and cisplatin has also shown promise, with cisplatin strongly suppressing the HSF-
1 activation by 17-AAG [194]. These two agents act synergistically, leading to an 
increased tumor cell apoptosis as compared to the use of each agent alone [194]. 
Furthermore, since HDAC6 histone deacetylase is required for HSF-1 activation [201], 
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there is the prospect that HSP90 inhibitors might act synergistically with HDAC 
inhibitors in promoting the growth arrest and apoptosis of tumor cells. Small molecule 
inhibitors that act directly on HSF-1 have also been identified, including the natural 
flavonoid quercitin [202,203] and the benzylidene lactam compound KNK437 [204].  
 
1.6.4.4. Other HSP90 inhibitors 
 
The soluble stabilized hydroquinone form of 17-AAG, IPI-504 (retaspimycin 
hydrochloride) is currently in clinical trials. Evaluation of this drug was done in 
gastrointestinal stromal tumor, which is usually driven by the HSP90 client protein KIT, 
where the drug showed promising results [205]. In addition, encouraging activity has 
been seen in non–small cell lung cancer (NSCLC) patients and clinical evaluations in this 
setting are ongoing[206].  
 
The tremendous success of work with geldanamycin analogs stimulated the race to 
discover synthetic small-molecule HSP90 inhibitors that could overcome some or all of 
the limitations of this class, such as by allowing the use of doses and schedules that 
provide sufficiently sustained client depletion while sparing the liver toxicity [207,208]. 
A large number of new HSP90 inhibitors that do not suffer from these constraints are 
now in clinical development.  
 
Investigators seeking to discover new HSP90 drug candidates have benefited greatly 
from structure-based design using available X-ray crystal structures of HSP90 [209,210]. 
Success was achieved early on with the purine scaffold series, which was based initially 
on the prototype PU3 [211,212]and led to the clinical candidates BBIIB021 (CNF-2024) 
and BIIB028, as well as PU-H71 [213], now under evaluation in phase I clinical trials. In 
addition the resorcylic pyrazoles and isoxazoles led to development of NVP-
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AUY922/VER52296, the resorcylic dihydroxybenzamide AT13387, and the structurally 
related KW-2478 [196,214]. A diverse range of chemical scaffolds have since emerged, 
as illustrated by the publication of 40 to 70 patents per year from 2005 to 2010, covering 
purines and resorcinols as well as pyrimidines, aminopyridines, azoles, and other 
chemotypes [215]. These include SNX-5422, which is a prodrug of the active benzamide 
SNX-2112, the orally active thienopyrimidine NVP-BEP800/VER-82576, the 8-
arylthiopurine CUDC-305, which is orally bioavailable, blood-brain barrier–permeant, 
and active in an orthotopic brain tumor model, and the N-aryltropane XL888 [216-219]. 
Another promising agent currently in multiple clinical trials is STA-9090 [ganetespib] 
[220]. Although its full structure is undisclosed, it is thought to be a resorcinol-containing 
triazole.   
 
The various new agents have the potential to be administered more frequently and to 
achieve a higher maximum dose (and hence better/more-prolonged target inhibition), in 
some cases with oral administration and blood-brain barrier penetration. New drugs also 
lack the significant hepatotoxicity that was limiting for members of the geldanamycin 
chemotype, consistent with this side effect being related to the quinone in those agents 
(see above) [206]. Encouraging early clinical data have been reported concerning these 
agents' pharmacodynamic and antitumor activities in diverse malignancies, again with the 
expected client protein and genetic profiles, including breast, NSCLC, and rectal cancer, 
as well as in melanoma and leukemia [163,185,221,222].  
 
As we learn more about the role of HSP90 in modulating signaling networks and the 
sensitivity of various client proteins to HSP90 inhibition, a better understanding of 
HSP90 biology has already educated and will continue to inform the ongoing clinical 
development of HSP90 inhibitor-based therapy, in part by supporting the correct choice 
of tumor types and revealing additional molecular targets whose inhibition synergizes 
with HSP90 inhibition [165].   
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Although to date the vast majority of drug development efforts have focused on targeting 
the N-domain ATP binding site of HSP90, a second druggable site has been identified in 
the C-domain of the protein [223,224]. Coumarin antibiotics, such as novobiocin, are the 
prototypic inhibitors that interact at this site. Recently, investigators have made 
significant advances in improving the affinity of these compounds for HSP90 and have 
shown their ability to induce apoptosis in cancer cells, in some cases with superior 
efficacy compared with tanespimycin [225,226]. One potential benefit of these drugs is 
that some of the C-terminal inhibitors seem to be associated with significantly less-robust 
HSF1 activation than is characteristic of N-terminal inhibitors [227]. Existing data 
strongly support further medicinal chemistry optimization and preclinical evaluation of 
C-terminal HSP90 inhibitors.  
When taken together, these data show that several tumor suppressor pathways may be 
deregulated following HSP90 inhibition. They further emphasize that the cumulative 
impact of an HSP90 inhibitor on both the individual and the cancer cell is multifactorial 
and will almost certainly be influenced by the duration of treatment, the disparate 
sensitivity to HSP90 inhibition of the various client proteins present in normal and cancer 
cells, the dependence of the particular cancer on the continued expression of one or more 
of these clients, and the local environmental context in which HSP90 inhibition occurs. 
Nonetheless, with these caveats in mind, the promising clinical responses that continue to 
be seen with several HSP90 inhibitors in a number of molecularly defined cancers 
certainly support the continued therapeutic development of these agents [165].  
Although targeting HSP90 in cancer patients in order to achieve a significant therapeutic 
benefit is still a work in progress, a number of highly potent and pharmaceutically 
improved HSP90 inhibitors that avoid some of the drawbacks of the first-generation 
inhibitors, as discussed above, are now in clinical trial. In the long term, realizing the full 
therapeutic potential of HSP90 inhibitors may require concomitant inhibition of HSP70 
isoforms or blockade of HSF1. In addition, differentiating tumors by client protein status 
and HSP90 expression level, more complete genetic profiling of tumors as a basis for 
patient selection, and careful HSP90 combinational therapies will help guide the field to a 
more efficacious use of HSP90 inhibiting drugs [165].  
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1.7. Cancer Immunity 
1.7.1. Immunosurveillance: Immune response to cancer   
 
The relationship between immune system and tumors is a complex one, as cells of the 
immune system can inhibit tumor progression, but under different circumstances, can aid 
tumor progression and angiogenesis as well. Immunodeficiency can predispose to tumor 
development, as observed in the case of Rag -/- mice [228]. In addition, established 
tumors often generate immunosuppressive microenvironments that can block productive 
antitumor immunity. Through a deeper understanding of the complicated relationship 
between tumors and the immune system, tumor immunology strives to harness the 
immune system to generate protective antitumor responses in patients [229,230]. 
 
Although the importance of antitumor immunity is most evident when considering 
tumors of viral origin, inherent immunodeficiencies in both mice and humans are 
associated with an increased incidence of tumors with no known infectious etiology, 
suggesting a role for spontaneous immunity in preventing tumor development . Extensive 
work in experimental systems has elucidated some of the mechanisms underlying 
spontaneous antitumor immunity, and has formed the basis for the cancer immunoediting 
hypothesis. This hypothesis divides the immune response to cancer into three phases: 
“elimination,” “equilibrium,” and “escape” [231]. The elimination phase occurs early 
during tumor growth, when productive antitumor immunity can efficiently eradicate 
malignant cells, preventing the growth of tumors. Based on work in animal models, 
tumor elimination by the immune system appears to involve the production of IFNγ, as 
well as the generation of tumor-reactive cytotoxic T cells. Several strains of 
immunodeficient mice, including mice lacking T cells and mice deficient in IFNγ, are 
also more susceptible to sporadic tumor development [232,233]. The second phase – 
equilibrium - occurs after a tumor has been established.  During this phase, antitumor 
immunity effectively inhibits tumor progression, but does not fully eradicate the tumor, 
 37 
leading to a stable disease stage. Recent studies in mice treated with low dose MCA have 
identified a subset of animals that develop tumors, which do not progress. Although these 
tumors remain stable for months in the absence of therapy, transient suppression of the 
adaptive immune system can induce rapid tumor growth, indicating that these stable 
tumors were controlled by adaptive immunity [232,233]. Following the equilibrium 
phase, tumors evolve to escape the immune response, enabling progressive tumor growth. 
Most tumors reach clinical attention after entering the escape phase, explaining the 
absence of effective, spontaneous antitumor immune responses in most patients [234]. 
 
Several lines of evidence suggest that, similar to animal models, spontaneous antitumor 
immunity can play a role in cancer patients. Immune infiltrates are common in many 
cancers, and infiltrates comprising activated CD8+ and memory CD45RO+ T cells have a 
strong correlation with a favorable prognosis. Several types of cancer are associated with 
distinct autoimmune syndromes, and cancer patients who have autoantibodies without 
frank autoimmune disease have improved prognosis. Equilibrium between tumor growth 
and immune rejection may also occur in some patients  [235].  
   
1.7.2. Tumor mediated immune suppression 
 
The microenvironment of many tumors is highly immunosuppressive which presents a 
substantial barrier to tumor immunotherapy. The microenvironment of tumors is 
established through the coordinated activity of regulatory myeloid and lymphoid cells, as 
well as the secretion/expression of immune suppressive factors by tumors themselves. 
Tumor cells often secrete immunosuppressive cytokines, including IL-10, TGF-beta, PG-
E2 and VEGF; these cytokines not only inhibit cytotoxic immune responses, but may also 
promote the formation or recruitment of additional regulatory cells [236]. In addition, 
unidentified tumor-derived factors modulate phosphorylation levels of signal transducers 
and activators of transcription (STAT)-3 and indoleamine 2,3-dioxygenase (IDO) 
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expression in DCs, resulting in so-called “tolerogenic” DC. IDO enzymatically depletes 
tryptophan, resulting in T cell anergy and in the apoptotic death of activated T cells due 
to the production of toxic metabolites, including kynurenines. Constitutive expression of 
IDO by tumors has also been reported and found to negatively impact T cell vitality and 
function within the tumor microenvironment [237,238].  
 
A broad range of genetic alterations in tumor cells that have been linked to 
“immunoevasion”. Tumor cells may develop insensitivity against IFNγ produced by DCs, 
NK cell and T cells [232,239]. Loss of TRAIL (death receptor signaling) expression has 
also been observed to contribute to tumor cell survival in the face of active immunity 
[240]. 
 
It is also known that tumor cells down-regulate many molecules involved in the 
processing and presentation of antigenic peptides in MHC class I complexes [241,242]. 
For example, high variability in expression has been reported for human leukocyte 
antigen (HLA)-class I expression among ascitic cells from ovarian carcinoma, and for 
transporters associated with antigen processing (TAP) and β-2 microglobulin (β2m) on 
tumor cell lines [243]. Although, tumors exhibiting low levels of MHC class I expression 
may conversely be targeted by natural killer (NK) cells, tumor cells may also shed tumor 
associated stress-induced ligands (MICA and MICB), which can bind to activating NK 
cell receptors, such as NKG2D, and cause tumor lysis [244]. In addition, tumor cells may 
acquire expression of T cell death/inhibitory inducing molecules such as FasL and B7-
H1. B7-H1 is a co-stimulatory molecule that can also inhibit activated PD-1+ effector T 
cells, is also frequently expressed on tumor cells in situ [245,246]. 
 
Tumor-derived (TD) exosomes can also exert immunoinhibitory effects and can be 
isolated from tumors and bodily fluids from patients with cancer. Tumors reported to 
release exosomes include cancers of the breast, oral cavity, colorectum, brain, ovary, 
bladder, prostate, and melanomas [247,248]. Exosomes contain molecules of the 
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neoplastic cells of origin, for example, urinary exosomes have molecular features of 
associated urologic malignancies, and exosomes from patients with melanomas contain 
Melan A/Mart 1 ([248]). TD exosomes variably contain epidermal growth factor receptor 
(EGFR), EGFRvIII, HSPs 27, 60, 70, 72, 73, 80, and 90 ([247,249,250], tumor necrosis 
factor alpha (TNFα), Fas ligand (FasL), and TGFβ [250,251]. 
Some tumors release exosomes that express FasL and/or tumor necrosis factor–related 
apoptosis-inducing ligand (TRAIL; refs. [252-256]) and these can cause apoptosis in 
activated T cells [252,253,255-257]. In addition, TD exosomes containing TGFβ1 cause a 
downregulation of the NKG2D receptor, which is an activating receptor for NK and 
CD8+T cells [258]. Thus, tumors-derived exosomes can partially suppress immune 
reactions using multiple mechanisms.  
Because exosomes from DCs can potentiate crosspresentation of antigens to specific T 
effector cells that are capable of attacking tumor cells and limiting tumor growth and 
metastasis. [248,259-261], TD exosomes could mediate profound immunosuppression via 
their inhibition of APC function. In support of this, TD exosomes cause time-dependent 
inhibition of the maturation of immature DCs via a dose-dependent, increased expression 
of IL-6 and phosphorylation of Stat 3 [262,263].  
In addition, HSP90A is released by invasive cancer cells in the form of exosomes, which 
can activate plasmin, a protease important in cancer cell invasion. 
Suppression of tumor immunity by CD4+ Tregs, which was originally described in the 
early 1980s, was largely ignored. However, the demonstration that Treg depletion in 
mouse models of cancer improves endogenous immune-mediated tumor rejection and 
tumor antigen–specific immunity quickly rekindled interest in the role of Tregs in tumor 
immunopathology [264,265]. Further work demonstrated that Treg depletion augments 
tumor immunotherapy, including vaccination and cytotoxic T lymphocyte–associated 
antigen 4 (CTLA4) blockade, and even augments immunologic rejection of brain tumors, 
which are difficult to treat using immunotherapeutic approaches because of the blood-
brain barrier [266,267]. Tregs can inhibit tumor-specific CD8+ and CD4+ T cell effector 
functions through incompletely understood mechanisms including cell-cell contact and/or 
the production of soluble factors such as IL-10 or TGF-β [268-270]. Numbers of Tregs 
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are increased in the blood and populate the tumor mass and draining lymph nodes of 
patients with many different cancers. Interestingly, tumor cells may release chemokines, 
such as CCL22 and SDF-1, which attracts Tregs into tumor sites in vivo [271-278]. 
Exosomal suppression of immunity may also be caused by a transition of CD4+, CD25− T 
cells to CD4+, CD25+, Foxp3+ T-regulatory cells (Treg) via intrinsic phosphorylation of 
SMAD2/3 and Stat3. Such interactions in peripheral tissues mediated by TD exosomes 
may participate in the maintenance of a state of immune tolerance [279-281]. 
Tregs are of two origins — natural and adaptive. Natural CD4+CD25+ Tregs arise in the 
thymus under homeostatic conditions to safeguard against autoimmunity. Adaptive 
CD4+CD25+ Tregs arise during inflammatory processes such as infections and cancers  
and suppress immunity through heterogeneous mechanisms that include direct contact or 
the production of soluble factors such as IL-10 and TGF-β [282]. Tregs that infiltrate the 
tumor microenvironment are probably adaptive. The tumor itself and cells in the tumor 
microenvironment, such as DCs, induce the differentiation of Tregs through various 
mechanisms including the production of TGF-β and the expression of B7-H1 [283,284]. 
Different pathways of Treg differentiation in tumors probably lead to heterogeneous 
populations of infiltrating Tregs. At least some tumor-associated Tregs are specific for 
tumor antigens, although once activated, they can also suppress tumor antigen–
independent immune responses though bystander mechanisms [285,286]. In addition to 
inhibiting the function of T cells, Tregs also inhibit the function of NK cells, B cells, and 
other immune cells, making Tregs an attractive inhibitory target for cancer therapy [287]. 
  
In addition to Tregs, certain myeloid lineage cells residing in the tumor stroma may 
down-modulate immune responses and/or directly support tumor growth. The myeloid 
derived suppressor cells (MDSCs), discovered by Bronte et al. as a population of cells 
expressing the markers Gr1 and CD11b. MDSCs represent an intrinsic part of the 
myeloid-cell lineage and are a heterogeneous population that is comprised of myeloid-
cell progenitors and precursors of myeloid cells [288]. In healthy individuals, immature 
myeloid cells (IMCs) generated in bone marrow quickly differentiate into mature 
granulocytes, macrophages or dendritic cells (DCs). In pathological conditions such as 
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cancer, various infectious diseases, sepsis, trauma, bone marrow transplantation or some 
autoimmune disorders, a partial block in the differentiation of IMCs into mature myeloid 
cells results in an expansion of this population. Importantly, the activation of these cells 
results in the upregulated expression of immune suppressive factors such as arginase 
(encoded by ARG1) and inducible nitric oxide synthase (iNOS; also known as NOS2) and 
an increase in the production of NO (nitric oxide) and reactive oxygen species (ROS). 
Together, this results in the expansion of an IMC population that has immune suppressive 
activity; these cells are now collectively known as MDSCs [289]. Their accumulation has 
been documented in most patients and mice with cancer, where they are induced by 
various factors produced by tumor cells and/or by host cells in the tumor 
microenvironment. MDSC are considered a major contributor to the increased immune 
dysfunction of most patients with sizable tumor burdens. In tumor-bearing mice MDSC 
accumulate in the bone marrow, spleen, and peripheral blood, within primary and 
metastatic solid tumors, and to a lesser extent in lymph nodes. In cancer patients they are 
present in the blood, and it is not known whether they are present in other sites [290-293]. 
In both patients and experimental animals MDSC levels are driven by tumor burden and 
by the diversity of factors produced by the tumor and by host cells in the tumor 
microenvironment. Exosomes also increase MDSC development/maintenance via TGFβ 
and regulation of prostaglandin E2 (PGE2). In addition, HSP72 in exosomes may interact 
with toll-like receptor 2 and MyD88 expressed by MDSCs, leading to the activation of 





Cancer immunotherapy is the use of the immune system to reject cancer. The main idea is 
stimulating the patient's immune system to attack the malignant tumor cells that are 
responsible for the disease. This can be either through immunization of the patient (e.g., 
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by administering a cancer vaccine), in which case the patient's own immune system is 
trained to recognize tumor cells as targets to be destroyed, or through the administration 
of therapeutic antibodies as drugs, in which case the patient's immune system is recruited 
to destroy tumor cells by the therapeutic antibodies. Cell based immunotherapy is another 
major entity of cancer immunotherapy. This involves immune cells such as the Natural 
killer Cells (NK cells), Lymphokine Activated killer cell (LAK), Cytotoxic T 
Lymphocytes(CTLs), Dendritic Cells (DC), etc., which are either activated in vivo by 
administering certain cytokines [296,297].  
 
Many kinds of tumor cells that arise as a result of the onset of cancer are more or less 
tolerated by the patient's own immune system since the tumor cells are essentially the 
patient's own cells that are growing, dividing and spreading without proper regulatory 
control. In spite of this fact, however, many kinds of tumor cells display unusual antigens 
that are either inappropriate for the cell type and/or its environment, or are only normally 
present during the organisms' development (e.g. fetal antigens). Other kinds of tumor 
cells display cell surface receptors that are rare or absent on the surfaces of healthy cells, 
and which are responsible for activating cellular signal transduction pathways that cause 
the unregulated growth and division of the tumor cell. Examples include ErbB2, a 
constitutively active cell surface receptor that is produced at abnormally high levels on 
the surface of breast cancer tumor cells [298,299]. 
 
1.8.1. Monoclonal antibody therapy 
 
Antibodies are a key component of the adaptive immune response, playing a central role 
in both in the recognition of foreign antigens and the stimulation of an immune response 
to them. It is not surprising therefore, that many immunotherapeutic approaches involve 
the use of antibodies. With monoclonal antibodies, it possible to raise antibodies against 
specific antigens such as the unusual antigens that are presented on the surfaces of 
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tumors. A number of therapeutic monoclonal antibodies have been approved for use in 
humans by the U.S. Food and Drug Administration (FDA) [297]. 
 
Alemtuzumab is an anti-CD52 humanized IgG1 monoclonal antibody indicated for the 
treatment of Chronic lymphocytic leukemia (CLL), the most frequent form of leukemia 
in Western countries. The function of CD52 is unknown, but it is found on >95% of 
peripheral blood lymphocytes and monocytes. Upon binding to CD52, alemtuzumab 
initiates its cytotoxic effect by complement fixation and antibody-dependent cell-
mediated cytotoxicity mechanisms [300]. Bevacizumab is a humanized IgG1 monoclonal 
antibody, which binds to and interferes with the vascular endothelial growth factor-A 
(VEGF-A), preventing receptor activation. Bevacizumab is indicated for colon cancer; 
but has been applied to numerous other cancers, especially renal cell carcinoma. Results 
obtained showed that bevacizumab increased the duration of survival, progression-free 
survival, the rate of response and the duration of response in a statistically relevant 
manner [301]. Rituximab is a chimeric monoclonal antibody specific for CD20. CD20 is 
widely expressed on B-cells. The exact mode of action of rituximab is also unclear, but it 
has been found to have a general regulatory effect on the cell cycle and on immune-
receptor expression. Experiments involving primates showed that treatment with anti-
CD20 reduced peripheral B-cells by 98%, and peripheral lymph node and bone marrow 
B-cells by up to 95% [302]. Trastuzumab is a monoclonal IgG1 humanized antibody 
specific for the epidermal growth factor receptor 2 protein (HER2). It received FDA-
approval in 1998, and is clinically used for the treatment of breast cancer. The use of 
Trastuzumab is restricted to patients whose tumors over-express HER-2, as assessed by 
immunohistochemistry (IHC) and either chromogenic or Fluorescent in situ hybridization 





1.8.1.1. Advances in monoclonal antibody immunotherapy 
 
The development and testing of second generation immunotherapies are already under 
way. The targeted delivery of cytokines by anti-tumor antibodies is one example of using 
antibodies to delivery payloads rather than simply relying on the antibody to trigger an 
immune response against the target cell. Another strategy is to deliver a lethal radioactive 
dose directly to the target cell, which has been utilized in the case of the Zevalin 
therapeutic agent. Still another strategy is to deliver a lethal chemical dose to the target, 
as used in the Mylotarg therapeutic agent. Engineering the antibody-chemical pair in such 
a way that they separate after entry into a cell by endocytosis can potentially increase the 
efficacy of the payload. One strategy to accomplish this is the use of a disulfide linkage 
that could be severed by the reducing conditions in the cellular interior. However, recent 
evidence suggests that the actual intracellular trafficking of the antibody-payload after 
endocytosis is such to make this strategy not generally applicable. Other potentially 
useful linkage types include hydrazone and peptide linkages [305].  
 
1.8.2. Adoptive T cell therapy 
1.8.2.1. T-cell adoptive transfer 
 
Adoptive cell transfer uses T cell-based cytotoxic responses to attack cancer cells. T cells 
that have been stimulated or genetically engineered reactivity to a patient's cancer are 
generated in vitro and then transferred back into the cancer patient. One study using 
autologous tumor-infiltrating lymphocytes was an effective treatment for patients with 
metastatic melanoma [306]. This was achieved by taking tumor-infiltrating lymphocytes 
(TILs) that are trained to multiply in vitro using high concentrations of IL-2, anti-CD3 
and allo-reactive feeder cells. These T cells are then transferred back into the patient 
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along with exogenous administration of IL-2 to further boost their anti-cancer activity. So 
far, a 51% objective response rate has been observed; and in some patients, tumors 
shrank to undetectable size [307,308].   
 
The initial studies of adoptive cell transfer using TIL, however, revealed that persistence 
of the transferred cells in vivo was too short [309]. Before reinfusion, lymphodepletion of 
the recipient is required to eliminate regulatory T cells as well as normal endogenous 
lymphocytes that compete with the transferred cells for homeostatic cytokines [310-312]. 
Transferred cells expanded in vivo and persisted in the peripheral blood in many patients, 
sometimes achieving levels of 75% of all CD8+ T cells at 6–12 months after infusion. 
Clinical trials based on adoptive cell transfer of TILs for patients with metastatic 
melanoma are currently ongoing at a handful of institutes around the world [313].  
 
1.8.2.2. Genetically engineered T cells 
 
Genetically engineered T cells may be created by infecting patient's cells with a virus that 
contain a copy of a T cell receptor (TCR) gene that is specialized to recognize tumor 
antigens. The virus is not able to reproduce within the cell however integrates into the 
human genome. A patient's own T cells are exposed to these viruses and then expanded 
non-specifically or stimulated using the genetically engineered TCR. The cells are then 
transferred back into the patient and are ready to have an immune response against the 
tumor. Morgan et al. have demonstrated that the adoptive cell transfer of lymphocytes 
transduced with retrovirus encoding TCRs that recognize a cancer antigen are able to 
mediate anti-tumor responses in patients with metastatic melanomas. This therapy has 
been demonstrated to result in objective clinical responses in patients with refractory 
stage IV cancer [314]. The Surgery Branch of the National Cancer Institute (Bethesda, 
Maryland) is actively investigating this form of cancer treatment for patients suffering 
aggressive melanomas (Steven Rosenberg, personal communication). The use of adoptive 
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cell transfer with genetic engineered T cells is a promising new approach to the treatment 
of a variety of cancers.  
 
1.8.2.3. TIL therapy 
 
Adoptive transfer therapy with TILs requires the isolation of T cells from fresh patient 
biopsy specimens and the progressive selection of tumor-specific T cells ex vivo using 
high levels of IL-2 and various cell culture approaches. The adoptive transfer of these 
cells showed promise in preclinical models, but clinical experiences, with perhaps one 
exception, were almost uniformly disappointing [315-319]. However, recent studies at 
the National Cancer Institute suggest that prior host conditioning with chemotherapy 
increases the response to adoptive immunotherapy with TILs. When 13 patients with 
progressive metastatic melanoma were given cyclophosphamide and fludarabine, a drug 
regimen that is immunosuppressive but does not have anti-melanoma efficacy, 6 patients 
had partial responses as judged by Response Evaluation Criteria in Solid Tumors 
(RECIST), and 4 others had mixed responses, i.e., some of their tumors regressed but 
others remained [315,320]. This approximately 50% objective response was confirmed in 
a subsequent report from the same group [320]. Importantly, the TILs showed prolonged 
engraftment compared with TILs transfused to patients without prior treatment with these 
chemotherapeutics, and the levels of engraftment correlated with the clinical responses. 
Indeed, concomitant host immunosuppression seems to be important because only 34% 
of patients with melanoma who were treated with TIL administration and high-dose IL-2 
and who received no prior chemotherapeutic conditioning therapy to induce 
lymphodepletion achieved objective clinical responses in trials previous to the 
incorporation of host lymphodepletion [318]. Most of the responses were transient, and 
the patients had limited persistence of the transferred cells in those trials. Adverse effects 
in the lymphodepletion trial included opportunistic infections and the frequent induction 
of vitiligo and uveitis, presumably due to autoimmunity. However, at this point, the 
results are difficult to interpret, as the ability to successfully generate TILs for therapy 
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could be a predictive biomarker of a more favorable clinical outcome [321,322]. 
However, in the absence of a randomized clinical trial it is not possible to determine how 
much lymphoablative chemotherapy, high-dose IL-2 administration, and TIL therapy 
contributed to the promising results in these recent trials. If it is confirmed that 
lymphodepletion augments TIL efficacy, the results from recent trials indicate that 
induction of immunosuppression in the host improves the antitumor efficacy of adoptive 
TIL therapy [320,323].  
 
Technical issues with producing tumor-specific T cells currently present a formidable 
barrier to conducting randomized clinical trials using TILs. Only 30%–40% of biopsy 
specimens yield satisfactory T cell populations, and the process is labor and time 
intensive, requiring about 6 weeks to produce the T cells for infusion [313]. Furthermore, 
nearly all clinical experience with TILs has been with patients with melanoma because of 
the ready surgical availability of tumor biopsy tissue. However, should technical 
limitations of current tissue culture approaches be overcome, the recent studies indicating 
that the presence of TILs correlated positively with survival in ovarian and colorectal 
cancer [324] could extend the impact of this promising therapeutic approach to other 
commonly encountered epithelial cancers.  
 
1.8.2.4. T cells engineered to express tumor antigen–specific receptors. 
 
A principal limitation of adoptive T cell therapy for some tumors is that the tumors are 
poorly antigenic; therefore, neither T cells with high avidity for tumor-specific antigens, 
nor T cells with the desired specificity remain in the patient following chemotherapy. 
Two strategies to overcome this limitation are now being tested in the clinic. One 
approach has been to endow T cells with novel receptors by introduction of chimeric 
receptors that have antibody-based external receptor structures and cytosolic domains that 
encode signal transduction modules of the T cell receptor [325]. These constructs can 
function to retarget T cells in vitro in an MHC-unrestricted manner to attack the tumor 
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while retaining MHC-restricted specificity for the endogenous TCR. Three pilot clinical 
trials have recently been reported. A trial that tested T cells expressing a T body receptor 
specific for a folate-binding protein that is present on ovarian carcinoma cells indicated 
that the approach was safe, but poor expression and persistence of the transgene encoding 
the T body receptor were observed in vivo [268]. Similarly, a pilot study in children with 
neuroblastoma treated with autologous T cells retargeted for a tumor-associated adhesion 
molecule has indicated that the approach is safe but was limited by poor persistence of 
the T cells. In several of the patients in clinical studies, the engineered cells persisted for 
several days to weeks before elimination by host immune responses, indicating that a 
challenge for this approach is to prevent a host immune response from eliminating the 
adoptively transferred cells [268,326-328]. The other major issues with the approach 
currently involve improving receptor design by optimizing the ligand-binding domain 
and by trying to incorporate costimulatory signaling domains into the signaling molecule 
[328].  
 
T cells are also being transduced to express natural αβTCR heterodimers of known 
specificity and avidity against MHC-presented tumor antigens [329]. In the first clinical 
trial using this approach, T cells were engineered to express a TCR specific for 
glycoprotein 100 (gp100), and lymphodepleted patients with melanoma were given a 
single infusion of these engineered T cells followed by an infusion of IL-2 [314]. A 
concern with this approach has been that it might generate additional, novel receptor 
specificities by pairing of the transgenes with the endogenous TCR chains. It is 
encouraging that no toxicity was observed in the pilot trial, and promising persistence of 
the engineered T cells was observed in some of the patients. However, one issue that 
arose was low cell-surface levels of expression of the gp100-specific TCR, which would 
be expected to lower the avidity of the TCR and therefore to limit effector functions. 
Another general limitation of this approach for humans is that each TCR is specific for a 
given peptide-MHC complex, such that each vector would only be useful for patients that 
shared both MHC alleles and tumor antigens [330].  
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1.8.2.5. The future of adoptive therapy with engineered T cells. 
 
The field of adoptive therapy with engineered T cells is on the brink of substantial 
clinical advances that are now possible because of improved cell culture and gene 
transfer methods. The advent of lentiviral vectors has greatly increased the efficiency of 
human T cell engineering, and a recent pilot study with lentiviral engineered T cells that 
expressed an anti-sense HIV vector showed promise in patients infected with HIV. As 
mentioned above, insertional mutagenesis is a safety concern with any integrating viral 
vector. However, side-by-side tests in preclinical models indicate that lentiviral vectors 
are less prone to insertional mutagenesis [331-333]. Nevertheless, long-term 
observational studies with large patient safety data sets are required to determine the 
ultimate safety of this approach. Finally, a primary issue that could limit the ultimate 
efficacy of the approach is the immunogenicity of the proteins that the T cells are 
engineered to express; this is likely to be a larger problem in humans than in mice 
because activated human T cells, unlike mouse T cells, express MHC class II molecules 
and have been shown to function as effective APCs [334].  
 
1.8.3. DC-based vaccines 
 
Both immunity and tolerance are controlled by a network of professional APCs, the most 
important of which are known as DCs [335,336]. Tissue-resident DCs that capture 
pathogen-encoded antigens are activated by stimuli generated in the course of a 
pathogen-induced inflammatory response. Activation of DCs occurs in two phases, 
maturation and licensing, and is an essential step that enables the antigen-loaded DCs to 
migrate to the draining lymph nodes where they can activate T cells that recognize the 
antigens they are presenting (cognate T cells) [337]. Unlike infectious pathogens, tumors 
do not induce an effective inflammatory response conducive for optimal activation of 
DCs, and as a result the ensuing immune response is weak and ineffective. The primary 
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purpose of vaccinating individuals with cancer is to overcome this “defect” by channeling 
tumor antigens into DCs and providing the conditions for their optimal maturation into 
potent immunostimulatory APCs [338].  
 
One approach that is gaining increasing popularity among tumor immunologists is to 
immunize cancer patients with autologous, patient-derived DCs loaded with tumor 
antigens ex vivo. The underlying premise of this approach is that the efficiency and 
control provided by ex vivo manipulation of the DCs generates an optimally activated 
APC and a superior method for stimulating immunity in vivo as compared with more 
traditional vaccination methods. Recent years have witnessed rapid and remarkable 
progress in developing DC-based vaccines, however the field is yet to make remarkable 
strides towards long-term elimination of cancer [338].  
 
1.8.3.1. Ex vivo generation of immunocompetent DCs 
 
The era of ex vivo DC vaccines was ushered in by the pioneering work of Inaba, 
Steinman, and colleagues, demonstrating that mouse DCs can be cultured ex vivo from 
bone marrow precursors [339]. In a similar fashion, human DCs can be generated in 
culture from CD34+ hematopoietic progenitors and, more commonly, from peripheral 
blood–derived monocytes. For cancer vaccination, the goal is to generate ex vivo a 
population of antigen-loaded DCs that stimulates robust and long-lasting CD4+ and CD8+ 
T cell responses in the patient with cancer. What seems to be the rate-limiting step at 
present is the inability to fully recapitulate ex vivo the development of immunocompetent 
DCs, in particular the process of DC activation [340-342]. DC activation can be divided 
into two stages. In the periphery, immature DCs undergo a maturation process in 
response to inflammatory stimuli that gives the DCs the capacity to home to lymph 
nodes. DCs receiving the appropriate maturation stimuli upregulate expression of CC 
chemokine receptor 7 (CCR7) and become responsive to CC chemokine ligand 19 
(CCL19) and CCL21, chemoattractants produced in the afferent lymphatics and the 
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lymph node. When reaching the lymph node, antigen-loaded mature DCs undergo an 
additional activation step, termed “licensing,” in response to various stimuli, notably 
CD40 ligand (CD40L) which is expressed on cognate CD4+ T cells. For generating DC 
vaccines, therefore, the goal is to differentiate antigen-loaded DCs only to the point that 
they have acquired lymph node migratory capacity and become responsive to licensing 
stimuli when they reach the lymph node and encounter cognate T cells [343].  
 
Immature DCs express low levels of CCR7 and cannot migrate to lymph nodes as 
effectively as mature DCs, which express high levels of CCR7. However, injecting 
immature DCs into skin that has been pre-exposed to adjuvants  effectively induces the 
maturation of DCs in situ; the mature DCs then migrate to lymph nodes and, being 
superior to the ex vivo  matured DCs, activate antitumor immunity. In situ maturation 
offers a simpler, effective method for generating DCs for cancer immunotherapy 
[344,345]. Other agents such as heat shock proteins (HSPs) also enhance the maturation 
and migration of DCs, thereby eliciting the antitumor immunity of DC vaccines. A recent 
report found that Hsp70-like protein 1 (Hsp70L1), a novel HSP derived from human 
DCs, promotes the maturation and activation of DCs, as well as increases CCR7 
expression in DCs [346]. Furthermore, DCs pulsed with the recombinant fusion protein 
of Hsp70L1 and CEA (576-669) induce a more potent CEA (576-669)-specific CTL 
response than DCs pulsed with CEA (576-669) alone. Adoptive transfer of splenocytes 
from mice immunized with CEA (576-669)-Hsp70L1-pulsed DC inhibits tumor growth 
and prolongs the survival of colon carcinoma-bearing mice more markedly than 
splenocytes from mice immunized with CEA (576-669)-pulsed DCs. Thus, Hsp70L1 may 
be widely used as a Th1 adjuvant for enhancing the efficacy of DC vaccines for treatment 





1.8.3.2. Clinical trials with DC-based vaccines 
 
Multiple clinical trials have been carried out to date targeting different cancers using 
different methods of generating DCs, different antigens, and different antigen-loading 
techniques [348]. At this early stage of clinical development, no indication or evidence 
has been obtained that DC vaccines represent a method of stimulating protective 
immunity in cancer patients that is superior to other vaccination strategies. In most 
studies, a fraction of patients, often half or less, exhibited immune responses against the 
vaccinating antigen [349]. Despite occasional correlations between immunological and 
clinical responses in such single-arm clinical trials, it is not known whether the modest 
clinical responses were caused by the vaccination or whether they reflect patients with 
better prognoses capable of mounting immune responses. The field of DC vaccines 
suffered a serious setback when a phase III clinical trial in patients with stage IV 
melanoma failed to demonstrate that DC vaccination provided increased benefit 
compared with standard DTIC chemotherapy [350]. The overall response was low in both 
patient groups (DTIC, 5.5%; DC vaccinated, 3.8). The study was therefore discontinued. 
It is conceivable that the suboptimal nature of the cytokine cocktail maturation protocol 
discussed above might have had an important role in the failure of this trial. In addition, it 
is important to appreciate the fact that a DC vaccination protocol is a complex, multi-step 
process and that a myriad of seemingly trivial steps such as how the cells are frozen and 
thawed, how long the cells are matured, the mechanics of their administration, and the 
time intervals between boosting can have a critical impact on the outcome of the 
treatment [338].  
 
Another example offering a glimpse at the promise of DC vaccines is the clinical 
experience of Vieweg and colleagues, in which patients with prostate cancer vaccinated 
with DCs transfected with mRNA encoding tumor antigens such as PSA or TERT and 
patients with renal cancer vaccinated with DCs transfected with unfractionated tumor-
derived mRNA developed tumor antigen–specific CD8+ T cell responses. Virtually all 
vaccinated patients responded immunologically with the induction of measurable T cell 
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responses [351-354]. Furthermore, clinically related responses, such as reduction in PSA 
levels, were often seen in the vaccinated patients in the prostate cancer trials. As an 
indication of things to come, in a recent phase I/II clinical trial, Dannull et al. were able 
to show that partial removal of Tregs can further potentiate DC vaccine–induced immune 
responses in cancer patients [351].  
 
Nevertheless, many immunologists maintain that DC vaccination remains a promising 
therapy for cancers; with a deeper understanding of DC biology, antitumor immunity, and 
the immune escape mechanisms, numerous novel and improved DC-based vaccines have 
been developed. These endeavors eventually led to the approval of the first DC vaccine, 
sipuleucel-T (Provenge) for the treatment of prostate cancer, by the US FDA in 2010 
[355]. Sipuleucel-T is a perfect example of a DC vaccine used in translational medicine: 
several cycles of “ bench to bedside and then back to bench” happen, during which the 
basic scientific understanding is applied to clinical treatments for cancers and then 













1.9.  SCOPE OF THE THESIS 
The studies performed in this thesis were designed to assess the efficacy of integrating 
HSP90 inhibition with EphA2-specififc immunotherapies. Specifically, I looked at the 
ability of HSP90 inhibitor 17-DMAG to increase the presentation of EphA2-derived 
peptides in the context of MHC class I molecules on the tumor cell surface in order to 
break tumor-mediated immune tolerance. HSP90 is a critical protein for tumor growth 
and survival, giving HSP90 inhibition a distinct operational advantage – deregulation of 
multiple pro-tumorigenic pathways apart from increasing susceptibility of the tumor to 
the host immune system. My findings indicate that 17-DMAG enhances recognition of 
both tumor cells and tumor-associated stromal cells by HS90 client protein-specific 
CD8+ T cells. In addition, treatment of tumor-bearing mice with 17-DMAG for a short 
duration also increased the infiltration of inflammatory immune cells into the tumor site 
over a prolonged period of time. Integration of 17-DMAG in combination  
immunotherapeutic regimens targeting tumor EphA2 led to improved anti-tumor efficacy 
in vivo. I believe this work supports a general therapeutic paradigm allowing for the 
combined immune targeting of a broad range of tumor cell (over)expressed HSP90 client 
proteins such as survivin, p53, etc.,, thus rendering this approach extremely versatile for 
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2.1. ABSTRACT 
HSP90 is an important chaperone molecule that binds multiple oncoproteins that play  
important roles in tumorigenesis and vasculogenesis. In tumors, HSP90 stabilizes and 
mediated the proper (re)folding of these “client” proteins. Therefore, inhibiting the action 
of HSP90 using 17-DMAG would be expected to induce the concomitant degradation of 
multiple HSP90 clients including RTKs mediated by the proteasome. However, along 
with RTKs, various signaling molecules, especially ones that mediate immunological 
processes are also known to associate with HSP90, and these could also be 
downregulated upon inhibition of HSP90 function. Indeed, HSP90 inhibition mediated by 
geldanamycin and 17-AAG (predecessors of 17-DMAG) have been observed to perturb T 
cell function and antigen presentation mediated by DCs. In the current study, I 
investigated the effects of 17-DMAG on a range of RTKs (over)expressed by a number 
of unrelated tumor cell lines. In addition, I looked at the effect of 17-DMAG on immune 
cell phenotype and function in vitro. 17-DMAG induced a dose-dependent decrease in 
RTK expression in all tumor cell lines tested, indicating the general versatility of the 
drug. When I studied its effects on immune cells in vitro, 17-DMAG treatment at higher 
doses (or longer treatment duration) affected DC phenotype and function, as well as the 
ability of naïve T cells to become activated. These studies indicate that while using 17-
DMAG to inhibit HSP90 could be a versatile approach for targeting multiple 
oncoproteins, the dose and duration of 17-DMAG treatment needs to be carefully 




Receptor tyrosine kinases (RTK) are important for various cell processes like cell growth, 
differentiation and survival [9]. In tumors, RTKs are frequently overexpressed, leading to 
constitutive on-signaling and deregulated neoplastic growth and survival [1,356]. 
Mutated and overexpressed RTKs in tumor cells depend on the HSP90 co-chaperoning 
machinery for sustained protein stability and functionality [4]. Therefore, inhibiting 
HSP90 via the use of pharmacologic agents would lead to the simultaneous 
destabilization and degradation of multiple RTKs coordinately expressed in a given 
tumor cell, leading to broad spectrum inhibition of oncogenesis. HSP90 antagonism (and 
ultimately RTK degradation) leads to the uncoupling of pro-tumor pathways – including 
those linked to sustained growth and migration (i.e. metastasis) [5,6,182].  
 
In addition to RTKs, HSP90 is known to interact with an extended list of client proteins 
(http://www.picard.ch/downloads/Hsp90interactors.pdf) that play important roles in cell 
signaling and in regulating the apoptotic cell death of normal as well as tumor cells [148]. 
Thus, inhibiting the function of HSP90 would lead to perturbed expression of anti-
apoptotic proteins like Bcl-xl, resulting in the clinically-preferred demise of tumor cells 
[357]. However, even normal cell functions could be compromised by administration of 
HSP90 inhibitors; i.e. HSP90 has also been reported to aid in antigen presentation of 
peptides and the generation of specific immune responses (as a result of antigen 
crosspriming).  A number of HSP client molecules have been reported to play roles in 
productive immune cell signaling (e.g. Zap70 is a signaling molecule that plays a role in 
TCR-mediated signaling, while NF-KB is a master transcription factor that mediated the 
transcription of a host of genes mediating an inflammatory immune response) [358-360]. 
Indeed, pharmacological HSP90 inhibitors have been observed to inhibit antigen 
presentation and to dampen immune responses [361]. In fact, HSP90 inhibitors have been 
touted as treatment options for patients with autoimmune diseases [362].  
  
Hence, in some ways, clinical use of HSP90 inhibitors would be viewed as 
counterintuitive in the context of immunotherapeutic approaches. It should be mentioned 
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that the aforementioned studies were performed using Geldanamycin and 17-AAG, 
which have been generally observed to be markedly more toxic than 17-DMAG which I 
have used exclusively in my work. The increased toxicity of these predecessor drugs 
could be due to the fact that they had to be dissolved in organic solvent (DMSO) prior to 
administration, In contrast, 17-DMAG, is readily dissolved in water and exhibits greater 
bioavailability after ingestion [182]. The aims of the experiments performed in this 
chapter were two-fold: 1) to evaluate the effect of 17-DMAG on RTKs in addition to 
EphA2 in multiple tumor cell lines and 2) to determine any dose-dependent negative 
effects of 17-DMAG on immune cells like T cell and DC viability and function 
 
2.3. MATERIALS AND METHODS 
2.3.1. Tumor cell culture 
MCA205 (sarcoma), B16 (melanoma), MC38 (colon carcinoma) and 4T1 (breast cancer) 
cell lines were purchased from the American Type Culture Collection. Cell lines were 
cultured in complete media [CM; RPMI 1640 supplemented with 100 units/mL penicillin, 
100 μg/mL streptomycin, 10 mmol/L l-glutamine, and 10% heat-inactivated fetal bovine 
serum (Life Technologies)] in a humidified incubator at 37°C and 5% CO2. All cell lines 
were negative for known mouse pathogens and mycoplasma infections.  
 
2.3.2. 17-DMAG treatment 
HSP90 inhibitor 17-DMAG (NSC 707545) was obtained from National Cancer Institute 
(NCI). Lyophilized 17-DMAG was dissolved in sterile water as stock solution and 
diluted with RPMI 1640 before use. 17-DMAG at the required final concentration was 
added to cell culture in 6-well plates for 24 or 48 hours before termination of cell culture.  
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2.3.3. Western blot 
Tumor cell lines were incubated with a range of 17-DMAG concentrations (10-500 
nmol/L) in complete RPMI 1640 (CM) for 24 to 48 h. To assess the effect of proteasome 
function in protein degradation promoted by 17-DMAG, MG-132 (50 μmol/L; Peptides 
international) was added 3h prior to 17-DMAG addition. Harvested cells were then 
incubated with lysis buffer (1% Triton X-100, 150 mmol/L NaCl, 10 mmol/L Tris-HCl 
(pH 7.4), 1 mmol/L EDTA, 0.2 mmol/L sodium orthovanadate, 0.5% NP-40 in PBS; all 
reagents from Sigma-Aldrich) containing a protease inhibitor cocktail (Complete mini; 
Roche Diagnostic) for 30 min at 4°C. Lysates were cleared by centrifugation at 13,500 × 
g for 10 min, and proteins in the lysate were separated by SDS-PAGE before electro-
transfer onto polyvinylidene difluoride membranes (Millipore). Polyclonal anti-Her2 
antibody, anti-VEGFR2 and anti-PDGFRB antibodies and horseradish peroxidase–
conjugated goat anti-rabbit antibody (all from Santa Cruz Biotechnology) were used to 
detect the different RTKs. Probed proteins were visualized by Western Lighting 
chemiluminescence detection kit (Perkin-Elmer) and exposed to X-Omat film (Eastman 
Kodak) for 5-7 min.  
 
2.3.4. T cell stimulation following 17-DMAG treatment 
Spleens from naïve C59BL6/J mice were excised and dispersed into single cell 
suspensions. CD4+ or CD8+ cells were isolated by incubating the splenocytes with 
magnetically labeled anti-CD4 or anti-CD8 beads, respectively, and passing labeled cells 
through a magnetic column. The positively labeled cells were then flushed out of the 
column and washed three times with serum-free media before being cultured in Complete 
media (CM) with different concentrations of 17-DMAG (or left untreated) for 24 or 48 
hours. After treatment, the cells were washed thoroughly with serum-free media and 
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stimulated with anti-CD3 at a concentration of 0.2 µg/well for 72 hours. Cell-free 
supernatants were harvested and assessed for levels of mIFNγ using a specific OptEIA 
ELISA set (BD Biosciences) as previously described. Data are reported as the mean ± 
SEM of quadruplicate determinations.  
 
2.3.5. Effect of 17-DMAG on DC phenotype and function 
BMDCs were obtained by differentiating cells from bone marrow of naïve C57BL6/J 
mice with GM-CSF and IL-4 for 7 days. CD11c+ DCs were isolated by MACS as 
described earlier. DCs were cultured in complete medium with different concentrations of 
17-DMAG for 24 or 48 hours, after which, the phenotype of the DCs was assessed by 
flow cytometry. To determine their ability to stimulate T cells, 17-DMAG treated or 
untreated DCs were co-cultured with allogenic T cells (from naïve Balb/c mice) for 48 
hours. The cell-free supernatant from this culture was assessed for levels of mIFNγ using 
a specific OptEIA ELISA set (BD Biosciences) as previously described. Data are 
reported as the mean ± SEM of quadruplicate determinations.  
 
2.3.6. Flow cytometry 
Before all stainings, cells were Fc blocked with anti-CD16/CD32 antibody (Becton 
Dickinson). Single-cell suspensions were stained using the following antibodies: APC -
conjugated CD11c (eBioscience), FITC-conjugated H2-Kb and I-Ab (Becton Dickinson), 
PE-conjugated CD40, CD80 and CD86 (all BD bioscience), DAPI (Sigma) or matched, 
fluorochrome-labeled isotype control monoclonal antibody (mAb). Cells were analyzed 
using an LSR II flow cytometer (Beckman Coulter), with data analyzed using FlowJo 
software (version 7.6.1; Tree Star, Inc.).  
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2.3.7. Statistical analysis 
All comparisons of intergroup means were performed using a two-tailed Student's t test, 
with P < 0.05 considered significant.  
 
2.4. RESULTS 
2.4.1. Degradation of RTKs upon 17-DMAG treatment 
I first investigated the effect of 17-DMAG treatment on tumor cell expression of a 
number of RTKs known to be important for tumorigenesis and vasculogenesis  (i.e. Her2, 
PDGFRβ and VEGFR2) in a variety of tumor cell lines (i.e. MC38 colon carcinoma, B16 
melanoma, and MCA205 sarcoma cells). In all cases, 17-DMAG was observed to 
mediate a dose-dependent degradation of RTKs, as exemplified in the case of EphA2, 















Cell lines MCA205 (sarcoma), B16 (melanoma) and MC38 (colon carcinoma) were 
treated with the indicated concentrations of 17-DMAG for 24 hours. After treatment, 
cells were lysed and assessed for RTK expression by Western Blot. Numbers indicate 
fold decrease vs untreated samples   
 63 
2.4.2. 17-DMAG affects phenotype of DCs 
Treatment of BMDCs with 17-DMAG appeared to result in changes in expression of 
MHC class I and class II molecules on DCs at higher doses (> 500 nm/L) compared to 
untreated DCs (Figure 7). The effect was observed to be more pronounced after 48 hours 
of treatment (versus 24 hour treatment). A similar effect of 17-DMAG was observed on 
other DC markers viz. CD40, CD80 and CD86 that play important costimulatory roles in 
T cell activation (Figure 6). Thus, in all, 17-DMAG was observed to affect DC surface 
markers that could potentially affect their function. To test if this effect was due to the 
increased toxicity of the drug (causing DC death) or due to its capacity to deregulate 
intrinsic signaling pathways in DCs, I repeated these experiments and stained the cells 
with DAPI in addition to the cell-type specific surface markers. When I evaluated the 
expression of DC surface markers after gating on DAPI-positive (live) cells, I did not 
observe any differences in expression of the assessed markers between treated versus 
untreated cells, suggesting that increased cell death in DCs was a possible reason for the 




Figure 6: : 17-DMAG treatment decreases expression of co-stimulatory molecules on DCs 
DCs were treated with 500nM (green histograms), 10 μM (blue histograms) or left 
untreated (red histograms) for 24h (top panel) or 48 hours (bottom panel). The markers 
evaluated were CD80 (left), CD86 (middle) and CD40 (right), with quantitation 
performed using flow cytometry. 
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Figure 7: High doses of 17-DMAG affect MHC molecule expression on DCs 
 
 
DCs were treated with 500nM (green histograms), 10 μM (blue histograms) or left 
untreated (red histograms) for 24h (top panel) or 48 hours (bottom panel) for MHC 




Figure 8: : Effect of 17-DMAG on DC phenotype is due to increased cell toxicity 
 
 
2.4.3. 17-DMAG affects the ability of DCs to stimulate T cells 
To look at the effect of 17-DMAG on DC function, we pre-treated BMDCs with different 
doses of 17-DMAG for 24 or 48 hours, after which, the DCs were thoroughly washed and 
co-cultured with naïve CD3+ T cells in an allogenic model (Balb/c mice) for 72 hours. 
Cell-free supernatant was harvested from the co-culture and analyzed for IFNγ levels by 
ELISA. It was observed that 17-DMAG- treated DCs had a significantly reduced capacity 
to stimulate allogenic T cells when compared to untreated DCs. As observed in other 
cases, the strongest ability to stimulate T cells was observed at higher doses of 17-
DMAG and was more pronounced after 48 hours of drug treatment 
DCs were treated with 500nM (red histograms), 10 μM (green histograms) or left 
untreated (black histograms) for 24h. The markers evaluated were CD80 (left), CD86 
(middle) and CD40 (right), with live cell (DAPI+ cells) gated on and quantitation 
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Figure 9: : 17-DMAG affects the ability to DCs to stimulate allogenic T cells 
 
2.4.4. 17-DMAG affects the ability of naive T cells to become activated in vitro 
CD4+ and CD8+ T cells were isolated from naïve C57Bl6/J mice and treated with 
different doses of 17-DMAG for 24 or 48 hours before then being stimulated with 
mitogenic anti-CD3 antibody for an additional 48 hours. Cell-free supernatants were then 
harvested and assessed for IFNγ levels by ELISA. 17-DMAG treatment for 24 hours did 
not affect the ability of naïve T cells to become activated after CD3 ligation. However, 
CD8+ T cells pre-treated for 48 hours with 17-DMAG, even at low concentrations (i.e. 
100 nM), displayed a decreased ability to become mitogenically-activated, while CD4+ T 
cells appeared largely unaffected in this regard.  
DCs from C57BL/6 mice  were treated with different concentrations of 17-DMAG for 
24h (left) or 48h (right) and later co-cultured with splenocytes from allogenic Balb/c 
mice for 72 hours. The supernatants from the co-culture were assessed for IFNγ levels. 
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Figure 10: : 17-DMAG affects ability of naïve T cells to be stimulated 
 
Naïve CD4+(left) or CD8+ T cells  (right) were isolated from C57BL/6 mice and 
treated with different concentrations of 17-DMAG for 24h (top panel) or 48h (bottom 
panel) prior to being mitogenically activated using anti-CD3 mAb. 
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2.5. SUMMARY 
To investigate the versatility of the RTK down-regulating effects of 17-DMAG, I 
assessed the effects of this drug on different RTKs expressed on a range of tumor cell 
lines. I consistently observed that 17-DMAG treatment led to a coordinate and dose-
dependent degradation of multiple RTKs across the many cell lines examined. This 
suggests that my proposed combination therapy approach could be expanded to include a 
range of additional HSP90 client proteins as vaccine targets or inducers of specific T cells 
for use in adoptive co-therapy applications. 
Since my intent is to combine 17-DMAG with immunotherapies, I was also held 
accountable to look at this drug potential inhibitory action on immune cell phenotypes 
and function (i.e. in DCs and responding T cell populations). My results suggest that any 
negative influence of 17-DMAG is due to the increased death of immune cells, and not 
due to the dysfunction of these cell types. Overall, my results indicate that careful 
inspection of the dichotomous effects of 17-DMAG on tumor versus immune cell types 
had to be taken into account in order to properly and equitably gauge the likely 
translational utility of such treatment options in vivo. In this regard, a pharmacologic dose 
that balanced these effects would need to be determined in order to be translatioanlly 
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Limitations in CD8+ T cell recognition of tumor cells due to defects in their antigen 
processing machinery or the selection of variants expressing low or absent levels of 
cognate tumor antigens have been previously identified as impediments to effective 
cancer immunotherapy. Hence, treatment regimens that coordinately promote enhanced 
activation of anti-tumor CD8+ T cells, improved delivery of such effector cells into 
tumor sites, and augmented recognition of tumor or tumor-associated stromal cells by 
therapeutic CD8+ T cells, would be expected to yield greater clinical benefit. Using an 
MCA205 sarcoma model, I show that in vitro treatment of tumor cells with the HSP90 
inhibitor 17-DMAG results in the transient (proteasome-dependent) degradation of the 
HSP90 client protein EphA2 and the subsequent increased recognition of tumor cells by 
Type-1 anti-EphA2 CD8+ T cells. In vivo administration of 17-DMAG to tumor-bearing 
mice led to: i.) slowed tumor growth; ii.) enhanced/prolonged recognition of tumor cells 
by anti-EphA2 CD8+ T cells; iii.) reduced levels of myeloid-derived suppressor cells 
(MDSC) and regulatory T cells (Treg) in the tumor microenvironment (TME); and iv.) 
activation of tumor-associated vascular endothelial cells in association with elevated 
levels of Type-1 tumor infiltrating lymphocytes (TIL). When combined with EphA2-
specific active vaccination or the adoptive transfer of EphA2-specific CD8+ T cells, 17-
DMAG cotreatment yielded a superior tumor therapeutic regimen that was capable of 






Receptor tyrosine kinases (RTKs) are an extended family of cell surface proteins [9] that 
bind growth factors and hormones and play important roles in cell survival, growth, 
migration and differentiation [356]. In neoplastic/cancerous tissues, RTK overexpression, 
mutation and/or constitutive activation may result in uncontrolled proliferation and 
increased malignant phenotype [363]. EphA2 is an RTK that facilitates intercellular 
interactions via binding to its ligands ephrin- A1, -A3, -A4 and -A5 expressed on a 
proximal, opposing cell surface [363]. EphA2 is expressed primarily in cells of epithelial 
origin in a broad range of adult tissues including lung, spleen and kidney. In addition, 
EphA2 is expressed by activated endothelial cells and is associated with tissue 
neovascularization in adults [23,39,79]. Numerous studies have described EphA2 
overexpression in a variety of tumors including melanoma, renal cell carcinoma and 
colon carcinoma, where the degree of overexpression of this RTK has been linked to poor 
prognosis and increased metastatic potential [52,64,364]. As a consequence, EphA2 has 
become an attractive target for therapeutic intervention in patients with solid tumors [8]. 
Currently, there are several EphA2-centric therapeutic strategies contemplated for 
translation into clinical trials, including antibody-based strategies that antagonize the 
binding of EphA2 to its ligands or which block EphA2-mediated signal transduction 
[80,82,86,365,366]. Such approaches would inherently negate intrinsic EphA2-associated 
pro-tumor effects and provide a degree of (at least transient) therapeutic efficacy that is 
independent of the host immune system. However, since EphA2 protein levels are 
stabilized in tumor cells by HSP90 [4,7], a more therapeutically desirable situation would 
occur if one were to drive EphA2 degradation via the proteasome, enhancing the 
likelihood for enhanced MHC class I presentation of derivative peptide epitopes and 
improved recognition of tumor cells by EphA2-specific CD8+ T cells [2]. Since low-to 
moderate avidity EphA2-specific CD8+ T cells have been detected in the peripheral 
blood of patients with renal cell carcinoma or prostate carcinoma [92,93], levels of 
circulating CD8+ T cells could also be amplified by vaccination for improved immune 
targeting of EphA2+ tumor cells in vivo. I report that in vivo administration of the HSP90 
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inhibitor 17-DMAG enhances EphA2+ tumor cell recognition by specific CD8+ T cells 
for a period of several days, while concomitantly serving as: i.) a restrictor of MDSC and 
Treg, and ii.) an activator/normalizer of the blood vasculature in the TME. When applied 
in the context of active immunization or adoptive CD8+ T cell therapy, 17-DMAG co-
administration led to enriched frequencies of tumor infiltrating Type-1 (anti-EphA2) 
CD8+ T cells and coordinately improved treatment outcomes. 
 
3.3. MATERIALS AND METHODS 
3.3.1. Mice 
 
Six- to 10-week-old female C57BL/6 (H-2b), and male and female B6;129S6- 
Epha2tm1Jrui (EphA2-/-; H-2b) mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME) and maintained in the pathogen-free animal facility in the Biomedical 
Sciences Tower at the University of Pittsburgh. All animal work was done in accordance 
with a protocol approved by the Institutional Animal Care and Use Committee (IACUC). 
 
3.3.2. Tumor cell lines and tumor establishment.  
 
The EphA2+ MCA205 sarcoma and EphA2neg B16 melanoma (H-2b) cell lines were 
purchased from the American Type Culture Collection (ATCC; Manassas, VA). Cell 
lines were cultured in complete media [CM; RPMI 1640 supplemented with 100 
units/mL penicillin, 100 μg/mL streptomycin, 10 mmol/L L-glutamine, and 10% heat-
inactivated fetal bovine serum (all from Life Technologies, Grand Island, NY)] in a 
humidified incubator at 37°C and 5% CO2. All cell lines were negative for known mouse 
pathogens, including mycoplasma. Tumors were established by injection of 5 x 105 
MCA205 or 1 x 105 B16 tumor cells s.c. into the right flank of syngeneic mice, with 
tumor size (in mm2) assessed every 3 to 4 days thereafter. Mice were sacrificed when 
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tumors became ulcerated or they reached a size of 400 mm2, in accordance with IACUC 
guidelines. 
 
3.3.3. 17-DMAG-based therapy.  
 
HSP90 inhibitor 17-DMAG (NSC 707545) was obtained under a material transfer 
agreement from the Division of Cancer Treatment and Diagnosis at the National Cancer 
Institute (Bethesda, MD). For in vivo use, tumor-bearing mice were orally administered 
17-DMAG or distilled water in a total volume of 50 μL, approximately 18 days after 
tumor inoculation, when tumors were ~100 mm2 in area. 
 
3.3.4. Isolation of tumor, tumor-draining lymph node (TDLN), and spleen cells.  
 
Single-cell suspensions were obtained from mechanically-disrupted spleen and TDLN, 
and from enzymatically-digested tumors, as previously described [367]. Western blot. 
MCA205 cell lines were grown to 80-90% confluence and then incubated with 17-
DMAG (10-1,000 nmol/L) in CM for 24-48 h. To assess the impact of proteasome 
function and endosomal acidification on EphA2 protein degradation promoted by 17-
DMAG, MG-132 (50 μmol/L; Peptides International, Louisville, KY) and chloroquine 
(50 μmol/L; Sigma-Aldrich), respectively, were added to cells for 3h. After washing in 
PBS, cells were cultured in the presence of 17-DMAG (500 nM) for an additional 24h. 
Harvested cells were then incubated with lysis buffer, and cell-free lysates were resolved 
by SDS-PAGE prior to electro-transfer onto polyvinylidene difluoride membranes as 
previously described (17), prior to probing with polyclonal anti-EphA2 antibody and 
horseradish peroxidase-conjugated goat anti-rabbit antibody reagents (both from Santa 
Cruz Biotechnology, San Diego, CA). Probed proteins were visualized by the Western 
Lighting chemiluminescence detection kit (Perkin-Elmer, Waltham, MA) and exposed to 
X-Omat film (Eastman Kodak, Rochester, NY) for 5-7 min. 
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3.3.5. Immunization of EphA2 -/- mice to generate EphA2-specific CD8+ T effector 
cells. 
 
EphA2 -/- mice that are not tolerant to “self” EphA2 protein were vaccinated with 
syngeneic DCs (transduced with recombinant adenovirus encoding mIL-12p70 as 
previously described to generate DC.IL12; ref. [368]) alone or DC.IL12 pulsed with 
synthetic mEphA2671–679 (FSHHNIIRL; H-2Db class I-presented; ref. [96]) and 
mEphA2682–689 (VVSKYKPM; H-2Kb class I-presented; ref. 23) peptides on a weekly 
basis in the right flank. After 4 vaccinations, CD8+ splenic T cells (MACSTM-selected; 
Miltenyi Biotec, Auburn, CA) were analyzed for specific reactivity using CD107 
cytotoxicity and IFNγ 
ELISA assays. 
 
3.3.6. CD107 cytotoxicity assay.  
 
CD8+ T cells were co-cultured with MCA205 tumor cells (either derived from culture or 
single cell suspensions of excised tumors) for 6 hours in the presence of anti-CD107 
antibody (BD Biosciences, San Diego, CA). Monensin (Sigma-Aldrich) was added to the 
culture to prevent the re-internalization of exocytosed CD107 after the first hour of 
incubation (final concentration = 10 μM). Cultures were allowed to incubate at 37oC for 
an additional 5h before cell harvest and assessment of T cell-surface CD107 expression 
as monitored by flow cytometry. 
 
3.3.7. IFNγ analyses.  
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For tumor recognition assays, splenic CD8+ T cells were co-cultured with irradiated (100 
Gy) tumor cells for 48 hours, after which, cell-free supernatants were harvested and 
assessed for mIFNγ concentrations using a specific ELISA (BD Biosciences). The data 
are reported as mean + SD of quadruplicate determinations. In some assays, where 
indicated, bulk TILs/splenocytes were restimulated in vitro with irradiated (100 Gy) 
MCA205 cells for 5 days at a T cell-to-tumor cell ratio of 10:1 in CM supplemented with 
20 units/mL of recombinant human interleukin-2 (IL-2; Peprotech, 
Rocky Hill, NJ). Recovered T cells were then cultured in CM alone, with syngenic DCs 
alone, or DCs pulsed with EphA2 peptides at a 10:1 T cell-to-DC ratio. In additional 
assays, CD8+ TIL from B16 tumor lesions or CD8+ T cells from the spleens of 
vaccinated EphA2 -/- mice were cultured with flow-sorted CD31+ VEC isolated from 
enzymatically digested B16 tumors or tumor-uninvolved kidneys harvested from 
untreated or treated animals, as previously described [369]. T cells stimulated with 5 
μg/mL anti-CD3 (eBioscience, San Diego, CA) served as a positive stimulation control. 
In some assays, as indicated, 1 μg/well (final concentration of 5 μg/ml) of anti-Kb/-Db 
mAb or isotype control mAb (BD Biosciences) were added to assess the MHC class I-
restricted nature of target cell recognition by T cells. For intracellular IFNγ staining, T 
cells were assessed after a 6 h culture using an intracellular cytokine staining kit (BD 
Biosciences), with stained cells screened using an LSR II flow cytometer (Beckman 
Coulter) and data analyzed using FlowJo software (Tree Star, Inc.). Levels of IFNγ in 
culture supernatants were quantified by specific ELISA. 
 
3.3.8. Immunofluorescence staining and imaging.  
 
Tumor tissue was processed and sectioned as previously reported [369], followed by 
immunofluorescence staining and microscopy. The following primary antibodies were 
used for staining sections: rat antimouse CD31 (BD Biosciences), rabbit anti-mouse 
EphA2 (Santa Cruz Biotechnology, San Diego, CA), rat anti-mouse VCAM-1, goat anti-
mouse CXCL10 (R&D Systems, Minneapolis, MN). The following secondary antibodies 
were used: donkey anti-rat Alexa Fluor 488 (Molecular Probes, Eugene, OR), donkey 
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anti-goat Cy3 (Jackson ImmunoResearch, West Grove, PA), donkey anti-rat Cy3 
(Jackson ImmunoResearch), goat anti-rat Fab1 fragment Cy3 (Jackson 
ImmunoResearch), and goat anti-rat Alexa Fluor 488 (Molecular Probes). TUNEL 
staining for detection of apoptotic cells was performed using a cell death detection kit 
(Roche Diagnostics) per the manufacturer’s instructions. All tissue sections were briefly 
incubated with 4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) and then mounted. 
Images were captured using an Olympus Provis microscope (Olympus America, Center 
Valley, PA). Isotype control and specific antibody images were taken using the same 
level of exposure on the channel settings. Metamorph (Molecular Devices, Sunnyvale, 
CA) software was used for cell quantification. 
 
 
3.3.9. Flow cytometry.  
 
Before all cell stainings, Fc receptors were blocked with an anti- CD16/CD32 antibody 
(Becton Dickinson). Single-cell suspensions were stained using the following 
fluorescently-labeled antibodies: APC- or FITC-conjugated anti-CD4 and -CD8 
(eBioscience), FITC-conjugated anti-Gr-1, PE-conjugated anti-CD25, and FITC-
conjugated anti-CD11c (all Becton Dickinson); FITC-conjugated anti-Class Kb/Db, anti- 
Class I-Ab, anti-CD107a and anti-CD107b, PE-conjugated anti-IFNγ (all eBioscience) 
and APC-conjugated anti-CD11b and anti-Foxp3 (eBioscience); or matched, 
fluorochrome labeled isotype control monoclonal antibody (mAb). For Foxp3 
intracellular staining, CD4+ T cells were surface stained as described above and then 
further processed using an APC-conjugated anti-mouse/rat Foxp3 Staining kit 
(eBioscience) according to the manufacturer's instructions. Fluorescently-stained cells 
were assessed using an LSR II flow cytometer (Beckman Coulter), with data analyzed 
using FlowJo software (Tree Star, Inc.). 
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3.3.10. Statistical analysis.  
 
All comparisons of intergroup means were performed using a two-tailed ANOVA test, 
with P < 0.05 considered significant. 
 
3.4. RESULTS 
3.4.1. 17-DMAG affects tumor RTK expression and viability in a dose-dependent 
manner. 
 
17-DMAG is an HSP90 inhibitor currently being evaluated in phase I/II clinical trials 
[5,184-187]. In preliminary in vitro studies, I determined that treatment of tumor cells 
with 17-DMAG resulted in their loss of EphA2 protein expression, with a clear drug 
dosedependency (Fig. 11A). Expression of alternate tumor RTKs and known HSP90 
client proteins, such as erbB2/Her2 and VEGFR [1,4,7] was also inhibited by 17-DMAG 
treatment in a dose-dependent manner (data not shown). 17-DMAG-induced loss of 
EphA2 protein expression in MCA205 sarcoma cells was dependent on the proteolytic 
activity of the proteasome and was not related to the enzymatic action of 
endosomes/lysosomes. Hence, addition of the proteasomal inhibitor MG132 to cultures 
prevented tumor cell EphA2 degradation induced by 17-DMAG treatment, while addition 
of the lysosomal inhibitor chloroquine (CLQ) to cultures had no discernable effect on 17-
DMAG-associated EphA2 degradation (Fig 11B). Treatment of MCA205 cell cultures 
with 17-DMAG did not modulate the expression of MHC class I molecules on the tumor 
cell surface (Fig 11C) or tumor cell viability/apoptotic frequency (data not shown). 
Notably, EphA2-specific CD8+ T cells developed from EphA2 -/- mice (Fig. 12) 
demonstrated increased in vitro recognition of EphA2+ MCA205 (but not EphA2neg B16) 
tumor cells pretreated with 17-DMAG (Fig. 11D and Fig 12). 
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Figure 11: 17-DMAG promotes proteasome-dependent EphA2 protein degradation in 










MCA205 tumor cells were treated with various doses of 17-DMAG for 24h in vitro, then 
lysed, with EphA2 and control β-actin protein expression subsequently monitored by 
western blotting as described in Materials and Methods. NC; negative control lysate from 
EphA2neg B16 melanoma cells. In B, proteasome inhibitor (MG-132), but not lysosome 
inhibitor chloroquine (CLQ), blocks 17-DMAG (500 nM)- induced degradation of EphA2 
protein in MCA205 tumor cells. In C, treatment of MCA205 cells with 17-DMAG at the 
indicated doses for 24h (or 48h, data not shown) did not affect MHC class I expression on 
tumor cells. In D, 17-DMAG-treated EphA2+ MCA205 cells were better recognized 
versus control, untreated tumor cells by anti-EphA2 CD8+ T cells (developed from EphA2 
-/- mice, per Fig. 2 and Materials and Methods) in CD107 translocation assays as 




Figure 12: : EphA2-specific CD8+ T cells preferentially recognize DMAG-treated EphA2+ 




3.4.2. 17-DMAG promotes sarcoma regression in association with the altered 
immunophenotype of the MCA205 TME.  
 
To determine how 17-DMAG would affect the growth and immunophenotype of well-
established (~ 100 mm2, 18 day old) tumors, the HSP90 inhibitor was administered 
orally at doses of 10, 15, and 25 mg/kg once a day for 2, 3, 5, 7 or 10 consecutive days. 
As shown in Fig. 13A, untreated tumors displayed rapidly progressive growth, while 
A, EphA2 -/- (H-2b) were vaccinated with syngenic DC.IL12 pulsed with the EphA2671-679 and 
EphA2682-689 peptides as outlined in Materials and Methods. One week after the last 
vaccination, CD8+ splenocytes were harvested and co-cultured with PBS, syngenic splenic 
monocytes pulsed with irrelevant OVA peptide, or either of the individual EphA2 peptides 
used in the vaccination, or they were stimulated with mitogenic anti-CD3 mAb. After 24h, 
cell-free supernatants were analyzed for IFNγ by specific ELISA. Data from triplicate 
determinations is reported as mean +/- SD. These same CD8+ T cells were also analyzed for 
reactivity against syngenic MCA205 sarcoma (EphA2+) or B16 (EphA2neg) melanoma cells 
that had been left untreated or treated in vitro with 17-DMAG (500 ng/ml for 24h), with 
specific T cell responses detected in CD107 translocation (B) or IFNγ ELISA assays (C), as 
outlined in Materials and Methods 
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tumors in animals treated with 17-DMAG at 10 mg/kg grew more slowly. Tumors in 
mice treated with 17-DMAG doses > 15 mg/kg regressed during the 10 days of active 
drug administration. To analyze the immunophenotype of the TME, treated animals were 
sacrificed one day after the last dose of drug, with enzymatically-digested tumors 
analyzed for immune cell infiltrates and the ability of the freshly-isolated tumor cells to 
be recognized by EphA2-specific CD8+ T cells in vitro. I observed that all doses of 17-
DMAG were capable of transiently (maximal on day 5 post initiation of treatment) 
increasing the level of tumor infiltrating CD4+ (Foxp3neg; CD4eff) and CD8+ T effector 
cells, while reducing the levels of tumor-associated cells bearing a CD11b+Gr1+ MDSC 
or CD4+Foxp3+ Treg suppressor cell phenotype (Fig. 13B). 
 
Interestingly, in vivo-treated tumor cells were better recognized by anti-EphA2 CD8+ T 
cells, particularly after 5 days of treatment with 15 mg/kg of 17-DMAG, based on both 
the CD107 translocation and IFNγ production assays (Fig. 13C and 13D). Notably, 
treatment of animals for more than 5 consecutive days with 17-DMAG resulted in the 
gradual erosion of this optimal day 5 Type-1 immunophenotype in the TME. Based on 
these results, all subsequent experiments used a standard 17-DMAG treatment regimen 





Figure 13: Treatment of mice bearing established MCA205 tumors with oral 17-DMAG 
transiently promotes a therapeutically preferred immunophenotype in the TME and is optimally 








C57BL/6 mice bearing established MCA205 tumors (day 18; _100 mm2 mean tumor 
size) were left untreated or they were administered 17-DMAG (10, 15, or 25 
mg/kg/d for up to 10 days via oral gavage) and tumor size (mean + SD, 5 animals 
per group) monitored longitudinally. *, P < 0.05; **, P < 0.01 (ANOVA) for 15 or 
25 versus 10 mg/kg/d or untreated; not significant (ANOVA) for 15 versus 25 
mg/kg/d. B, tumors were excised on the indicated day after initiating treatment, and 
single-cell suspensions of enzymatic tumor digests analyzed for immune cell 
infiltrates by flow cytometry as described in Materials and Methods. Tumor cells 
isolated from enzymatic digests (per B) were also analyzed as target cells for anti-
EphA2 CD8. T effector cells generated from EphA2 -/- mice (see Fig. 2) as 
monitored using CD107 translocation (C) and IFN-γ secretion (D) assays as 
described in Materials and Methods. All data are representative of those obtained in 
3 independent experiments. For B–D, P < 0.05;  P < 0.01 (ANOVA) versus all other 
determinations. 
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3.4.3. The beneficial effects of 17-DMAG administration persist even after 
discontinuation of therapy on day 5. 
 
 To evaluate the durability of 17-DMAG-associated immunomodulation in vivo, 
MCA205 tumor-bearing mice were treated with 15 mg/kg of 17-DMAG for 5 days and 
then followed for up to 28 days. As shown in Fig. 14A, treatment with 17-DMAG 
promoted tumor regression through day 10 (5 days after drug discontinuation), after 
which time slow tumor growth was observed through day 28. Tumor expression of 
EphA2 protein in vivo was precipitously reduced during the drug treatment window and 
only began to return to control levels 10-15 days after the discontinuation of drug (Fig. 
14B). The ability of anti-EphA2 CD8+ T cells to recognize in vivo treated tumor cells 
remained significantly elevated through day 10-14 after treatment initiation (Fig. 14C) 
and the predominance of CD4+ and CD8+ T effector cells (and CD11c+ DC) over 
regulatory (MDSC and Treg) cells within the treated TME persisted through day 28 in 
these experiments (Fig. 14D). I also observed that 17-DMAG treated tumors displayed a 
prolonged, increase in expression of both VCAM-1 and the CXCR3 ligand chemokine 
CXCL10 in situ, even after discontinuation of this monotherapy (Fig. 15). Furthermore, 
TUNEL staining of tumor sections demonstrated increased frequencies of apoptotic cell 
death within the TME of 17-DMAG-treated versus untreated MCA205 lesions at all time 














Figure 14: The impact of 17-DMAG-based therapy for 5 days persists after discontinuation 




MCA205 tumor-bearing mice (5 mice/group) were left untreated or they were treated 
for 5 days with orally-administered 17-DMAG (15 mg/kg/day), with tumor growth 
then monitored over a 4 week period. B, EphA2 protein expression in tumors 
harvested from 17-DMAG-treated versus untreated mice was analyzed longitudinally 
by western blotting as outlined in Materials and Methods. C, Tumor cells from 
untreated or 17-DMAG-treated mice were analyzed at the indicated time points for 
their ability to be recognized by anti-EphA2 CD8+ T cells generated from EphA2 -/- 
mice (see Fig.2) in CD107 translocation and IFN-γ secretion assays, as described in 
Materials and Methods. D, Single cell suspensions from harvested tumor digests were 
analyzed by flow cytometry for the indicated T cell, DC and MDSC phenotypes. All 
data are representative of that obtained in 3 independent experiments. *p < 0.05 for 
treated versus untreated controls. 
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Figure 15: : DMAG promotes enhanced apoptosis and expression of VCAM-1 and CXCL10 
in the MCA205 tumor microenvironment 
 
3.4.4. Combination vaccination + 17-DMAG immunotherapy yields superior anti-
tumor efficacy.  
 
MCA205-bearing mice were untreated or treated with a 5 day course of 17-DMAG (15 
mg/kg/day provided via oral gavage per Fig. 3A). On the indicated days post-initiation of 
therapy, tumors were isolated from 2 mice/cohort and tissue sections analyzed for the 
indicated markers by fluorescence microscopy as described in Materials and Methods. 
Data derive from 1 of 3 experiments performed, with similar results obtained in each case. 
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Given 17-DMAG’s ability to promote the enhanced recognition of treated tumor cells by 
anti-EphA2 CD8+ T cell in vivo, and a protective immunophenotype within the TME, I 
hypothesized that a combination therapy based on active vaccination against EphA2 
protein along with 17-DMAG administration would provide superior efficacy against 
EphA2+ tumors. In such a paradigm, vaccine-induced, anti-EphA2 CD8+ T cells would 
be recruited into the TME based on the ability of 17-DMAG to activate tumor (VCAM-
1+) endothelial cells, to increase locoregional production of CXCL10, and to improve the 
ability of anti-EphA2 Tc1 to recognize MCA205 tumor cells with reduced antagonism 
from suppressor cell populations in vivo. As shown in Fig. 16A, the combination of 17-
DMAG administration plus active vaccination against EphA2 resulted in vastly superior 
anti-tumor efficacy when compared to treatment with either single modality. Indeed, this 
combination immunotherapy was the only treatment capable of rendering animals free of 
disease (in 8 of 10 cases; i.e. 80 %), with “cured” animals competent to reject a corollary 
re-challenge with MCA205 tumor cells (Fig. 16A). An analysis of TIL harvested from 
the various treatment groups supports the superior induction/recruitment of Type-1 anti-
EphA2 CD8+ T cells (Fig. 16B) and improved population of tumor lesions by CD4+ and 
CD8+ T effector cells and CD11c+ DC over regulatory immune cell subsets (Fig. 16C) 
after vaccine + 17-DMAG combination therapy. 
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Figure 16: 17-DMAG administration improves the immunogenicity and anti-tumor efficacy 
of an EphA2 peptide-based vaccine in the MCA205 tumor model 
 
 
C57BL/6 mice bearing established EphA2+ MCA205 sarcomas (s.c. right flank) 
remained untreated, or they were treated with DC-based vaccines (s.c., left flank on 
days -7 and 0 of the treatment regimen) that contained or lacked EphA2 peptide 
epitopes, alone or in combination with 17-DMAG (15 mg/kg/day on the first 5 days 
of the treatment regimen by Rao et al. oral gavage). Tumor size (mean +/- SD) is 
reported in mm2. All the mice in the DC/EphA2 + 17-DMAG-treated group rendered 
tumor-free (80%) were rechallenged (s.c., right flank) with MCA205 tumor cells on 
day 30 of the experiment (as indicated by arrow with “R” inset) and monitored 
through day 60 after treatment initiation. B, CD8+ TIL recovered from tumors on 
day 14 after treatment initiation were assessed for their ability to recognize syngenic 
control DC pulsed with no peptide or DC pulsed with the EphA2671-679 + EphA2682-
689 peptides. After 48h incubation, cell-free supernatants were analyzed for IFN-γ 
content by ELISA. Response to DC (no peptide) was < 50 pg/ml) in all instances. C, 
Single-cell suspensions of enzymatically-digested day 14 (post-treatment initiation) 
tumors were analyzed by flow cytometry for the indicated T cell, DC and MDSC 
phenotypes as described in Materials and Methods. Each filled circle represents data 
from an individual animal in a given control or treatment cohort, with the mean of 
data indicated by a gray bar for each cohort. All data are representative of those 
obtained in 3 independent experiments. *p < 0.05 versus all other cohorts. 
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We have previously shown that EphA2 peptide-based vaccination was capable of slowing 
the growth of EphA2neg B16 melanoma progression in syngenic mice (based on the 
hypothesized CD8+ T cell targeting of EphA2+ vascular endothelial cells in the TME; 
ref. 24). As a consequence, I next chose to evaluate whether the combined EphA2-based 
vaccine + 17-DMAG therapy established in the MCA205 model would provide a 
superior level of protection against B16 progression. As shown in Fig. 17A, DC/EphA2 
peptide vaccination or 17-DMAG alone served to slow B16 tumor growth, while the 
combination therapy led to disease stabilization for over 30 days after initiating 
treatment. Immunofluorescence microscopy and Metamorph quantitation of B16 tumor 
sections suggested fewer EphA2+CD31+ vascular endothelial cells (VEC) in animals 
treated with DC/EphA2 vaccine only, DMAG only and DC/EphA2 vaccine + DMAG, 
with the most striking reductions occurring in the DC/EphA2 vaccine + 17-DMAG 
cohort (Fig. 17B). To further investigate the therapeutic targeting of tumor-associated 
EphA2+ VEC in the B16 melanoma model, I isolated CD31+ VEC by flow-sorting from 
enzymatic digests of B16 tumors and/or tumor-uninvolved kidneys excised from 
untreated versus treated animals, and analyzed the ability of these target cells to be 
recognized by anti-EphA2 CD8+ T cells developed from EphA2 -/- mice (Fig. 17C) or by 
CD8+ TIL isolated from mice treated with the superior combined therapy (i.e. DC/EphA2 
peptide vaccine + 17-DMAG) 6 days after the initiation of treatment (Fig. 17D). I 
observed that anti-EphA2 Tc1 populations preferentially recognized tumor-associated 
VEC isolated from DMAG (+/- vaccine)- treated mice in an MHC class I-restricted 
manner (Fig. 17C), but these T cells failed to recognize tumor-uninvolved kidney-




Figure 17: 17-DMAG improves the anti-tumor efficacy of an EphA2 peptide-based vaccine 
in the EphA2neg B16 melanoma model based on immune targeting of EphA2+ VEC 
 
C57BL/6 mice bearing established s.c. B16 melanomas (right flank) were left 
untreated or treated as outlined in Fig. 7A, with tumor size (mean +/- SD) reported in 
mm2 followed for up to 30 days. *p < 0.05 versus all other cohorts. B, Day 14 (post-
treatment initiation) tumors were harvested and tissue sections analyzed by 
immunofluorescence microscopy and Metamorph quantitation for co-expression of 
CD31 (i.e. VEC) and EphA2 proteins as described in Materials and Methods. Anti-
EphA2 CD8+ T cells isolated from the spleens of immune EphA2 -/- mice (panel C; as 
outlined in Fig. 2), or TIL from B16 tumor-bearing animals treated with combined 
DC/EphA2 peptide vaccination + 17-DMAG (panel D; per Fig. 5A) were analyzed for 
reactivity against flow sorted CD31+ VEC isolated from the tumors of B16-bearing 
animals left untreated or treated for 6 days with DC/EphA2 vaccine only, 17-DMAG 
or DC/EphA2 vaccine + 17- DMAG. CD31+ kidney VEC were also flow sorted from 
animals treated for 6 days with DC/EphA2 vaccine + 17-DMAG to discern 
“autoimmunity” of T cells against tumor uninvolved VEC. In C, the MHC class I-
restricted nature of VEC recognition by CD8+ T cells was assessed by inclusion of 
anti-class I or isotype control mAb per culture well, as described in Materials and 
Methods. *p < 0.05 versus untreated controls (all panels) and versus replicate cultures 
containing blocking anti-MHC class I mAb (panel C). **p < all other cohorts (panel 
B). All data are representative of those obtained in 3 independent experiments. 
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3.4.5. Pre-conditioning the cancer-bearing host with 17-DMAG enhances the 
therapeutic efficacy of adoptively transferred anti-EphA2 CD8+ T cells.  
 
Based on the recent clinical successes for adoptive T cell transfer therapy in the cancer 
setting [306,314,370], I next examined whether 17-DMAG conditioning of the MCA205 
TME would improve the delivery and anti-tumor effectiveness of EphA2-specific CD8+ 
T cells delivered via i.v. injection. EphA2-specific CD8+ T cells were isolated from the 
spleens of EphA2 -/- mice previously vaccinated with syngenic DC pulsed with EphA2 
peptides (Fig. 12). Splenic CD8+ T cells from EphA2 -/- mice vaccinated with syngenic 
DC alone (no peptide) served as controls. The optimum time-point for injection of the 
therapeutic Type-1 EphA2-specific T cells (i.e. day 4) was determined empirically by 
performing adoptive transfers at various time-points after initiating 17-DMAG treatment 
(Fig. 18). I observed that adoptive transfer of EphA2-specific T cells 4 days after 
initiating a 5 day course of 17-DMAG (15 mg/kg/day) yielded superior anti-tumor 
protection when compared to all other treatment cohorts (Fig. 19A), in concert with 
improved levels of CD4eff and CD8+ TIL and reduced levels of tumor-associated 
regulatory cell populations (Fig. 19B), and the accumulation of anti-EphA2+ Tc1 in the 
MCA205 TME (Fig. 19C). I also noted that tumor core necrosis and ulceration occurred 
uniquely in animals treated with the combination of EphA2- immune T cells + 17-




Figure 18: 17-DMAG improves the anti-tumor efficacy of adoptively-transferred anti-






C57BL/6 mice bearing established s.c. MCA205 sarcomas (right flank) were left 
untreated or they were treated with 17-DMAG (15 mg/kg/day provided orally on the 
first 5 days of the treatment regimen) +/- adoptive transfer (i.v. tail vein on days 2, 4 or 
7 of treatment) of 5 x 106 CD8+ T cells isolated from EphA2 -/- mice previously 
vaccinated with DC.IL12 only (i.e. Control Immune T Cells) or DC.IL12 loaded with 
EphA2 peptides (i.e. EphA2 Immune T Cells) as described in Materials and Methods. 
Tumor size was monitored longitudinally and is reported (mean +/- SD) in mm2 from 5 
mice/group. In B, day 32 untreated or treated (as in panel A) tumors underwent 
enzymatic digestion, with CD8+ TIL analyzed for expression of intracellular IFN-γ by 
flow cytometry as described in Materials and Methods. *p < 0.05 versus all other 




Figure 19: 17-DMAG improves the anti-tumor efficacy of adoptively-transferred anti-
EphA2 CD8+ T cells in a combination therapy. 
 
C57BL/6 mice bearing established s.c. MCA205 sarcomas (right flank) were left 
untreated or they were treated with 17- DMAG (15 mg/kg/day provided orally on the first 
5 days of the treatment regimen) +/- adoptive transfer (i.v. tail vein on day 4 of the 
treatment regimen) of 5 x 106 CD8+ T cells isolated from EphA2 -/- mice previously 
vaccinated with syngenic DC (control T cells) or DC loaded with the EphA2671-679 + 
EphA2682-689 peptides. Tumor size was monitored longitudinally and is reported (mean +/- 
SD) in mm2 from 5 mice/group. All animals treated with combined anti-EphA2 (immune) 
T cell + DMAG therapy required euthanasia due to core necrosis on day 14 after 
treatment initiation. In B, day 14 untreated or treated tumors underwent enzymatic 
digestion, with single-cells analyzed by flow cytometry for the indicated T cell, DC and 
MDSC phenotypes as described in Materials and Methods. Each filled circle represents 
data from an individual animal/cohort with the data mean indicated by the gray bar. In C, 
CD8+ TIL harvested from day 14 (post-treatment initiation) tumors were analyzed for 
IFN-γ secretion in response to EphA2 peptide-pulsed syngenic (control) DC by ELISA as 
outlined in Materials and Methods. *p < 0.05 versus all other cohorts. All data are 




The major finding in this chapter is that the HSP90 inhibitor 17-DMAG functions as an 
immune adjuvant in the context of vaccines targeting the HSP90 client protein, EphA2. It 
appears to perform this function in at least 3 ways, by: i.) reducing suppressor cell 
populations such as MDSC and Treg within the TME, ii.) activating the tumor-associated 
vasculature and promoting locoregional production of chemokines (such as CXCL10) 
that recruit protective, Type-1 T effector cells, and iii.) enhancing the (proteasome-
dependent) processing of tumor EphA2 protein and subsequent recognition of these 
tumor (and tumor-associated VEC) by anti-EphA2 CD8+ T cells elicited by specific 
vaccination or provided via adoptive transfer. These therapeutically beneficial effects of 
orally administered 17-DMAG occurred rapidly, were maximal by day 5 of drug 
provision, and were sustained for a prolonged period of 1-3 weeks (depending on the 
specific index), as long as treatment with the HSP90 inhibitor was discontinued after a 5 
day course. 
 
Prolonged application of 17-DMAG for > 5 days appeared to result in the erosion of its 
potent adjuvant-like qualities by as early as day 7 in chronic treatment protocols. Why 
such immunologic silencing occurs upon extended 17-DMAG administration is currently 
unclear. However, previous studies have suggested the potential attenuating effects of 
high-dose, long-term dosing of 17-DMAG on the immune system [64,358,371]. I plan to 
intensively investigate the mechanism(s) underlying the deleterious effects of more 
“chronic” 17-DMAG administration in future studies. The capacity of this combination 
immunotherapy to target both EphA2+ tumor cells and/or VEC in the TME has important 
translational ramifications since EphA2+ cancer cells have been reported to be more 
migratory (greater metastatic potential; refs. [38,51,361]) and the immune regulation of 
tumor-associated blood vessels reduces concerns for the immunophenotypic status of the 
tumor cell population (i.e. variation in MHC and antigen expression by heterogeneous 
populations of tumor cells in the TME). The ability of this treatment strategy to facilitate 
immune targeting of stromal cells provides the possibility of effectively treating MHC I- 
or antigen-loss (as modeled by EphA2neg B16) tumor variants. 
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Importantly, 17-DMAG administration combined with either active vaccination to induce 
anti-EphA2 Tc1 in vivo (Fig. 16A, 17A) or the adoptive transfer of anti-EphA2 CD8+ T 
cells (Fig. 19A) proved therapeutically superior to any single component modality. Both 
combination protocols resulted in the rapid regression of well-established (~ day 18 
tumors), with a high rate of complete responses in the vaccine setting. Evidence of a 
protective memory CD8+ T cell response was evident, given the rejection of a subsequent 
tumor re-challenge in these mice. The only distinguishing clinical variable between the 
two immunotherapy approaches was the core necrosis observed only for tumors treated 
with the adoptive immunotherapy (AIT) approach. The simplest explanations for this 
biologic difference would reflect: i.) the comparative numbers of specific CD8+ T cells 
infiltrating tumors at early time points (i.e. presumed to be greater in the AIT protocol), 
ii.) the higher functional avidity of the anti-EphA2 Tc1 generated from the EphA2 (-/-) 
versus wild-type (self-tolerant) mice allowing these T effector cells to more efficiently 
recognize tumor cells or VEC expressing modest levels of MHC I-EphA2 peptide 
complexes on their cell surfaces in vivo, or iii.) possible variance in the poly-functionality 
of anti-EphA2 T cells in these treatment cohorts. We are investigating each of these 
intriguing possibilities in on-going experiments. 
 
HSP90 inhibitors, such as 17-DMAG (alvespimycin) have been investigated in multiple 
phase I/II clinical trials over the past several years. These drugs exhibited variable 
antitumor efficacy and toxicity when administered as single agents [186,187,372-374]. In 
a phase I study of 17-DMAG administered i.v. to patients with advanced solid tumors, 
objective clinical responses (including 1 complete response) based on RECIST criteria 
were reported in a minority of patients with kidney or prostate carcinoma, melanoma or 
chondrosarcoma [186]. Like many chemotherapeutic agents, HSP90 inhibitors fail to 
exert durable anti-cancer efficacy based on intrinsic disease resistance or the 
development of acquired resistance among treated populations of cancer cells [375-377], 
reinforcing the clinical need to evolve combinational therapeutic strategies. 
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Our data suggest that sustained therapeutic benefits can be obtained by combining a short 
(5 day) course of 17-DMAG treatment along with an immunotherapy promoting the 
CD8+ T cell targeting of EphA2+ cells in the TME. Given the clinical experience 
suggesting only moderate efficacy for single-modality HSP90 inhibitors, as well as for 
antigen-based vaccination in the cancer setting [186,187,378-380], combination protocols 
predicated on these individual treatment modalities would be anticipated to provide 
superior clinical benefits to patients. Although our modeling has been based on combined 
vaccine/AIT + 17-DMAG approaches focusing on disease-associated EphA2 protein, one 
could also clearly envision similar therapeutic protocols predicated on the immune 
targeting of one or more alternate HSP90 client proteins that are commonly 
(over)expressed by tumor cells or tumor-associated stromal cells, such as beclin 1, 
cyclinB, EGFR, HER2/neu, IGF1-R, PDGFR, PIM-1, STAT3, survivin, TGFβR, 
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We have earlier shown that the HSP90 inhibitor 17-DMAG can mediate degradation of 
RTKs through the proteasome and cause a subsequent increase in the presentation of 
RTK-derived peptides in the tumor MHC class-I complexes expressed on the tumor cell 
surface. This allows for specific recognition of treated tumor cells by low-to-moderate 
avidity CD8+ T cells that are otherwise “tolerant” to normal self tissues. However, our 
preliminary results have also demonstrated that at higher doses and/or longer treatment 
times, 17-DMAG can adversely affect immune cell phenotype and function in vitro. 
When we assessed the effect of 17-DMAG on immune system in vivo, we replicated our 
in vitro findings at higher doses/treatment durations. However, we also observed 
(unexpectedly) that treatment with 17-DMAG at lower doses over short periods of time 
circumvented tumor-mediated immune suppression and orchestrated the increased 
infiltration of pro-inflammatory cells into the tumor microenvironment. The aim of this 
study was to elucidate the mechanisms of 17-DMAG-mediated immune cell infiltration 
into tumors and to assess the anti-tumor efficacy of 17-DMAG in a combinational 
immunotherapy setting targeting the RTK EphA2. We observed that 17-DMAG 
treatment upregulated expression of type-1 immune response genes in treated mice, and 
downregulation of immune suppressive/pro-angiogenic genes. In addition, in 
combination with two separate immunotherapeutic approaches, 17-DMAG treatment 








17-DMAG is one of the more recently developed HSP90 pharmacological inhibitors, that 
is currently being evaluated in phase II clinical trials [186,187]. The biggest advantage 
17-DMAG offers over its predecessors is its ability to be dissolved in water, thus giving 
the drug far greater bioavailability [5,6]. As mentioned earlier, along with playing a pro-
tumorigenic role, HSP90 is known to foster inflammatory immune responses by directly 
impacting antigen presentation and immune cell activation [359,360]. Thus, even though 
my goal of using 17-DMAG was to inhibit HSP90 in order to block tumor growth and 
survival by affecting multiple tumorigenic and vasculogenic pathways, I was also 
concerned with potential inhibitory effects that this HSP90 inhibitor might have on 
immune responsiveness. If validated, such activity would be counterintuitive to my effort 
to achieve superior anti-tumor efficacy by combining 17-DMAG with EphA2-targeted 
immunotherapy.  
 
Therefore, I initiated these studies by first looking at the effect(s) of 17-DMAG on DCs 
and T cell function in vitro. I observed that although 17-DMAG did not have any 
undesirable effects on immune cell phenotype and function at low concentrations, at 
doses higher than 500nM, it could negatively affect T cell and DC function (Chapter 2, 
figs 6,7,9,10). I also noted that the effects were associated with increased immune cell 
death (Chapter 2, fig 8). When I investigated  the effects of 17-DMAG on immune cell 
infiltration in the tumors in vivo, I also observed that at high concentrations (>15 
mg/Kg/day) and when given over a prolonged dosing schedule (> 5 consecutive days), 
17-DMAG negatively affected immune cell infiltration into tumor lesions (Chapter 3, fig 
13).  
 
However, a more important (and unexpected) finding of my study was that treatment with 
a low dose of 17-DMAG for a short time increased infiltration of inflammatory T cells 
and DCs, and decreased the incidence of immunosuppressive cells like Tregs and 
MDSCs (Chapter 3, figs 13,14). Moreover, I observed that 17-DMAG treatment also led 
to increased expression of CXCL10 and VCAM-1 by tumor cells and the tumor-
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associated vasculature, respectively. In addition, these pro-inflammatory effects of 17-
DMAG were observed to persist even after 17-DMAG treatment was discontinued, for up 
to 28 days (Chapter 3. Fig 15).   
 
4.3. MATERIALS AND METHODS 
4.3.1. Mice 
 
Six- to 10-week-old female C57BL/6 (H-2b), and male and female B6;129S6-Epha2tm1Jrui 
(EphA2-/-; H-2b) mice were purchased from The Jackson Laboratory and maintained in 
the pathogen-free animal facility in the Biomedical Sciences Tower at the University of 
Pittsburgh. All animal work was done in accordance with a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC).  
 
4.3.2. Tumor establishment 
 
The MCA205 (H-2b) sarcoma cell line was purchased from the American Type Culture 
Collection. Cells were cultured in complete media [CM; RPMI 1640 supplemented with 
100 units/mL penicillin, 100 μg/mL streptomycin, 10 mmol/L l-glutamine, and 10% heat-
inactivated fetal bovine serum (Life Technologies)] in a humidified incubator at 37°C and 
5% CO2. Tumors were established by injection of 5 × 105 MCA205 tumor cells s.c. into 
the right flanks of syngeneic mice, with tumor size assessed every 3 to 4 days and 
recorded in mm2. Mice were sacrificed when tumors became ulcerated or reached a 
maximum size of 400 mm2 in accordance with IACUC guidelines. 
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4.3.3. 17-DMAG therapy 
 
For in vivo uses, 17-DMAG was obtained from Cancer Therapy Evaluation Program 
(CTEP- NCI) and dissolved in sterile water. Tumor-bearing mice were orally 
administered 17-DMAG or distilled water in a total volume of 50 μL approximately 18 
days after tumor inoculation when tumors were ~100 mm2 in area. The optimal dose and 
duration of 17-DMAG treatment was 15mg/Kg and 5 days respectively. 
 
4.3.4. Isolation of tumors 
 
Tumors were resected from 17-DMAG treated or untreated mice and  enzymatically 
digested with 0.1% (w/v) collagenase, 1% (w/v) hyaluronidase, and 0.1% (w/v) DNase 
(Sigma), and a single cell suspension was prepared. For isolation of tumor-infiltrating 
lymphocytes, tumor cells were loaded onto a lympholyte-M column (Cedarlane) and 
TILs were isolated as buoyant cells after discontinuous density gradient centrifugation as 
previously described [367].   
 
4.3.5. Western blot 
 
MCA205 tumor cells treated with 17-DMAG (or left untreated) were incubated with lysis 
buffer (1% Triton X-100, 150 mmol/L NaCl, 10 mmol/L Tris-HCl (pH 7.4), 1 mmol/L 
EDTA, 0.2 mmol/L sodium orthovanadate, 0.5% NP-40 in PBS; all reagents from Sigma-
Aldrich) containing a protease inhibitor cocktail (Complete mini; Roche Diagnostic) for 
30 min at 4°C. Lysates were cleared by centrifugation at 13,500 × g for 10 min, and 
proteins in the lysate were separated by SDS-PAGE before electro-transfer onto 
polyvinylidene difluoride membranes (Millipore). Polyclonal anti-STAT 3 and STAT 1 
antibodies and horseradish peroxidase–conjugated goat anti-rabbit antibody (both from 
Santa Cruz Biotechnology) were used to detect STAT 3 and STAT 1 respectively. Probed 
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proteins were visualized by Western Lighting chemiluminescence detection kit (Perkin-
Elmer) and exposed to X-Omat film (Eastman Kodak) for 5-7 min.  
 
4.3.6. Reverse transcription-PCR 
 
For semiquantitative reverse transcription-PCR (RT-PCR), tumors excised from 17-
DMAG treated (or untreated) animals were digested to form a single-cell suspension (as 
described earlier) and used for RNA isolation and cDNA preparation using random 
hexamer primers (Applied Biosciences). PCR was performed using the primer pairs listed 
in Supplementary Table S1. Cycling times and temperature were as follows: initial 
denaturation at 94°C for 2 minutes (1 cycle); denaturation at 94°C for 30 seconds, 
annealing at 60°C to 65°C for 30 seconds, and elongation at 72°C for 1 minute (35–40 
cycles); final extension at 72°C for 5 minutes (1 cycle). Following gel electrophoresis, 
PCR products were imaged and band density was quantified using LabWorks software 
(Perkin-Elmer).  
 
4.3.7. DC.IL12 gene therapy 
 
DCs were generated from mice bone marrow by differentiating with GM-CSF and IL-4. 
On day 5 of culture, the DCs were transduced with an adenoviral vector expressing 
murine IL12 for 48 hours. After transduction, 106 DCs were suspended in 100 μ1l and 
injected intra-tumorally in 17-DMAG treated/untreated mice on the last day of 17-
DMAG treatment.  
4.3.8. Immunization of EphA2 -/- mice to generate EphA2-specific T cells 
 
EphA2 -/- mice were vaccinated with syngeneic DCs transduced with IL12 pulsed with 
EphA2 peptides H-2Db-binding mEphA2671–679 (FSHHNIIRL) and H-2Kb-binding 
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mEphA2682–689 (VVSKYKPM) or non-pulsed DCs once a week or 15 days 
subcutaneously on the right flank. After 4 vaccinations, spleen was harvested and 
splenocytes in a single cell suspension were assessed for EphA2-specificity using a 
peptide recognition assay and for their function by CD107 cytotoxicity assay and tumor 
recognition IFNγ assay. For adoptive transfer, 5 x 106 CD8+ T cells were suspended in 
100ul of PBS and injected intra-tumorally (i.t.) into 17-DMAG treated/ untreated mice on 




4.4.1. 17-DMAG treatment induces overexpression of type 1 immune response genes 
Tumors isolated from mice treated with 17-DMAG exhibited increased expression of 
genes indicative of type 1 immune responses like T-bet and IFNγ, and decreased 
expression of immune suppressive factors like FoxP3, IL-10 and TGFβ. In addition, 17-
DMAG treated tumors also displayed increased levels of T cell recruiting chemokines 
and receptors such as CXCL9/10/11 and CXCR3, respectively. Importantly, 17-DMAG 
treatment decreased expression of pro-angiogenic factors like HIF1α/HIF2α, CXCL12 
(aka stromal derived factor-1-alpha; SDF-1α) and its receptor, CXCR4.  
17-DMAG treatment also slightly increased levels of p-STAT1 (associated with 
increased Type 1 immune function) and significantly decreased levels of p-STAT3  













































Figure 20: 17-DMAG treatment causes upregulation of type-1 immune response genes and 






Tumors from 17-DMAG treated/untreated mice were excised and were either used 
for making tumor cell lysates or RNA isolation. mRNA gene expression of type-1 (a), 
non-type-1 (b) and angiogenic genes (c) were assessed by RT-PCR. p-STAT1 and p-
STAT3 expression was assessed by western blot using specific antibody probes (d). 













4.4.2. Combinational therapy of 17-DMAG with EphA2-specfic immunotherapy elicits 
superior anti-tumor efficacy 
 
When 17-DMAG treatment was evaluated in combination with DC.IL12 gene therapy 
(DCs transduced with IL 12 and administered intratumorally on the last day of 17-
DMAG treatment), I observed that mice receiving combinational therapy displayed 
significantly slower tumor growth rates than mice receiving a single mode of treatment or 
untreated mice. In addition, when I analyzed tumor infiltrating T cells for EphA2 
specificity, I noted that mice treated with the combination therapy had significantly 
higher levels of EphA2-specific TILs. 
 
Combining 17-DMAG with intra-tumoral adoptive transfer of EphA2-specific T cells 
resulted in significantly greater anti-tumor efficacy when compared to mice treated with 
monotherapies. In fact, in mice receiving the therapeutic combination of 17-DMAG with 
intra-tumorally transferred EphA2-specific T cells, the tumors showed significant 
hemorrhagic necrosis and complete liquefaction, thus making post-treatment analysis of 





















a) MCA205-tumor bearing mice were treated with 17-DMAG at 15 mg/Kg for 5 days 
and DCs transduced with IL12 gene were injected intra-tumorally in appropriate groups 
on the final day of treatment, with tumors monitored for the remainder of the study. b) 
MCA205-tumor bearing mice were treated with 17-DMAG at 15 mg/Kg for 5 days and 
5x106 cells were injected intra-tumorally on the final day (5) of DMAG treatment.  
 
17-DMAG + DC.IL12 
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4.5. SUMMARY OF RESULTS 
 
17-DMAG treatment of tumor bearing mice led to extensive infiltration of inflammatory 
CD4s, CD8s and DCs into the tumor microenvironment. I attempted to discern the 
underlying mechanisms of action of 17-DMAG and observed that the drug induced 
increased expression of type1 inflammatory genes and decrease expression of 
immunosuppressive factors within tumors. In addition, there was an increase in  
expression of anti-angiogenic factors and a concomitant decrease in pro-tumor 
angiogenic factors (HIFs, CXCL12, CXCR4 etc.). While I have not yet elucidated the 
exact temporal sequence of events that underlies the benefits of 17-DMAG treatment, my 
limited understanding of the changes occurring in the tumor microenvironment following 
17-DMAG treatment has been enriched by the current study and is further expounded 
upon in General Discussion section of this thesis document. 
 
In view of the immune adjuvant properties of 17-DMAG, I looked at the effects of 
combinational 17-DMAG-based immunotherapy in a sarcoma tumor model and observed 
that mice receiving combinational treatment had significantly slower/reduced tumor 
growth when compared to animals receiving single modes of treatment. In fact, when 
combined with the adoptive transfer of EphA2-specific T cells, this approach led to tumor 
liquefaction and hemorrhagic necrosis. Hence, combining 17-DMAG with EphA2-
targeted immunotherapy could represent a particularly effective therapeutic approach for 




CHAPTER 5.  GENERAL DISCUSSION 
Expression of receptor tyrosine kinases (RTKs) is upregulated in a number of cancers, 
where these molecules play important roles in tumorigenesis and vasculogenesis by 
mediating sustained tumor growth, angiogenesis and metastasis [1,9]. EphA2 is one such 
RTK that is overexpressed by both tumors as well as the tumor-associated vasculature, 
with its degree of overexpression linked to poor disease prognosis and an increased 
incidence of metastasis [8]. Given such clinical correlates, I have dedicated my Ph.D. 
project to defining means to effectively target and to modulate EphA2 expression in the 
tumor microenvironment via the induction of protein degradation, leading to enhanced 
immunity and reduced tumor growth and metastasis (as a consequences of negatively 
impacting tumor angiogenesis).  
 
In tumors, HSP90 plays a central role in mediating the proper folding and stabilization of 
a range of oncoproteins (including RTK such as EphA2), with such target proteins 
considered to represent HSP90 “clients” [3,148,161]. Due to the post-translational action 
of HSP90 molecules, EphA2 protein can become overaccumulated in tumor cells. My 
work, and that of others in our laboratory indicate that agents like small molecule HSP90 
inhibitors (i.e. 17-DMAG) and anti-EphA2 agonistic antibodies can effectively promote: 
1) EphA2 degradation by re-route it for processing by the proteasome (instead of the 
lysosome), with the caveat that Ub-EphA2 would need to be onvestigated further in this 
regard, 2) possible loading/presentation of higher levels of EphA2-derived peptides (can 
only be truly validated using mass spectrometry applied to peptides extracted from 
affinity-purified tumor MHC class I molecules) and 3) the presentation of these MHC 
I/peptide complexes on the tumor cell surface. As a consequence, tumors treated with 
agonistic EphA2 antibody or 17-DMAG were observed to be significantly better 
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recognized by EphA2-specific (cloned or bulk) CD8+ T cell effector cells [2,7,382].  
 
Tumors have evolved a number of mechanisms to evade the host immune response. 
Therefore, a focus has been placed on countering these mechanisms in order to generate 
more effective anti-tumor immune responses [230]. Immunotherapy for the treatment of 
cancer has gained popularity in recent years, as has been detailed in the Introduction 
section to this thesis, with several therapeutic approaches demonstrating some degree of 
success in the clinic, including the i) adoptive transfer of genetically-engineered patient T 
cells recognizing tumor antigens and ii.) injection of vaccines based on the patient’s own  
dendritic cells loaded with tumor antigens in order to effectively stimulate specific anti-
tumor T cells in vivo [306,338].  My studies as performed, did not allow me to 
discriminate whether improved T cell recognition also resulted (at least partially) due to 
HSP90 inhibitor-induced upregulation in tumor cell expressed costimulatory molecules 
or down-regulation of co-inhibitory molecules. These issues will need to be carefully 
evaluated in prospective studies. My research was also not designed to address the impact 
of HSP90 inhibitors on the level and composition of tumor-elaborated exosomes that may 
serve as regulators of immune responses by providing either negative signals or a source 
of antigen to fuel DC-based cross-presentation. Since HSP90 and RTKs are commonly 
found in tumor-derived exosomes, it is likely that HSP90 inhibitors will alter the nature 
of these vesicular mediators, thereby influencing both locoregional (to tumor) and 
peripheral immunity. These issues will need to be carefully assessed in future evaluations 
of single and combined modality HSP90 inhibitors in vivo. 
 
However, immunotherapies as a whole, have displayed only modest efficacy in the clinic, 
despite their common ability to enhance circulating frequencies of tumor-specific T cells 
in the blood of many treated patients. This may be attributed to the low-to-moderate 
avidity of the negatively-selected T cell repertoire (reactive against non-mutated, “self” 
RTK peptides) that is activated by such therapies. Such T cell populations may become 
effectively activated by APCs presenting abundant (high) levels of tumor antigen-derived 
peptides, but they typically fail to recognize tumor cells that naturally present low 
stochastic levels of relevant MHC/tumor peptide complexes on their cell surface [296]. In 
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addition, many tumors downregulate components of their antigen presenting machinery 
(APM), particularly components required for cell surface MHC class I/peptide 
complexes, thus further hindering their ability to be regulated by the (CD8+) T cell arm 
of the adaptive immune response [241]. 
 
Cancer is a multi-factorial disease resulting from accumulation of multiple gene 
mutations and the deregulated expression of proteins aligned with pro-survival and –
metastatic associated signaling pathways. Therefore, it is not surprising that in the clinic, 
the application of a single mode of treatment has resulted in limited effectiveness, as has 
been repeatedly observed in now thousands of clinical studies applied to patients with 
cancer [127,267]. The near-term future of tumor therapy lies in the development and 
clinical application of synergistic combination therapies that coordinately antagonist 
multiple survival, growth, metastatic pathways that are intrinsically important to 
heterogeneous populations of cancer cells within a given lesion in a given patient.  
 
As outlined in the Introduction, the HSP90 inhibitor 17-DMAG has been used in 
combination with chemotherapy or radiotherapy in order to improve the anti-tumor 
impact of each single modality, in part, by overcoming the development of tumor chemo-
/radio-resistance. Of note, 17-DMAG has been evaluated in combination with 
doxorubicin, cisplatin and HDAC inhibitors, with each of these combination therapies 
leading to improved treatment benefits when compared to either component single 
modality [191-193]. More recently, 17-DMAG has been used in combination with 
bortezomib (a proteasome inhibitor) as a improved treatment option in the setting of  
rhabdomyosarcoma [383]. Using this approach has demonstrated that inhibition of the 
proteasome re-routes the ubiquitinated proteins to the lysosomes for degradation. In 
addition, it has been reported that proteasome inhibition may activate autophagy which in 
turn may induce presentation of peptides on tumor MHC class I molecules [384]. This 
hypothesis, however, has not been confirmed in this study. HSP90 inhibition using 17-
DMAG is also showing great promise in treatment of tumor cells with mutant forms of an 
oncoprotein, that are resistant to conventional chemotherapeutic agents that 
recognize/target the wild-type oncoproteins [192]. For example, 17-DMAG has been 
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used in combination with TKIs targeting EGFR in patients with EGFR-mutant non-small 
cell lung cancer that develop drug-resistance based on a compensatory shift to a c-met 
(HGFR)-mediated survival/growth signaling pathway [385]. In addition, the combination 
of 17-DMAG with radiotherapy, with 17-DMAG abrogating G2  S phase transition 
and interfering with DNA damage repair in treated tumor cells. Ultimately, combination 
17-DMAG/radiotherapy has demonstrated significantly higher anti-tumor efficacy in 
vitro and in vivo compared to single agent administration in a number of tumor models, 
including lung and breast cancers [188,378]. Overall, 17-DMAG has shown great 
promise in the combinational therapeutic setting, however, its efficacy as an “adjunct” to 
immunotherapy had not been determined in vivo prior to the performance of the current 
studies.  
 
Based on our preliminary published data demonstrating that 17-DMAG treatment of 
EphA2+ human tumor cell lines leads to their increased recognition by specific, HLA-
A2-restricted CD8+ T cells in vitro [7], I hypothesized that combining 17-DMAG with 
an anti-EphA2 immunotherapy approach (either adoptively-transferred EphA2-specific T 
cells or the active immunization against EphA2 using a DC-based vaccine) would 
provide superior anti-tumor efficacy when compared to either component treatment alone 
in vivo. Since our foundational studies were performed using human tumor cells in vitro, 
I began my studies in mouse models by evaluating the effects of 17-DMAG in vitro. My 
work showed that 17-DMAG caused a dose-dependent decrease in EphA2 “client 
protein” levels upon treatment with 17-DMAG, with no adverse effects on tumor cell 
expression of MHC class I levels. Although this suggested (indirectly) that there was no 
negative impact on the tumor antigen-processing machinery (APM), I could not directly 
assess the effect of 17-DMAG on other components of the APM like TAP1, TAP2, etc., 
due to unavailability of validated, specific probes reactive against these murine proteins. 
Furthermore merely the analysis of the protein content would not speak to any variance in 
their functional capacity pre- versus post-treatment with 17-DMAG. Hence, as was the 
case for our human in vitro studies, I observed that 17-DMAG promoted the proteasome 
(but not lysosome)-dependent degradation of tumor EphA2 molecules that resulted in 
subsequent increase in the ability of anti-EphA2 specific CD8+ T cells to recognize these 
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target cells in vitro.  
 
As discussed in chapter 2, I also evaluated the effect of 17-DMAG on other RTKs – 
Her2/neu, VEGFR1 and PDGFRB across three different cell lines – MCA205 (sarcoma), 
B16 (melanoma) and MC38 (colon cancer). I found that, as was the case for EphA2, 17-
DMAG coordinately mediated the degradation of multiple RTKs in all of these cell lines 
in a dose-dependent fashion. This suggests that my studies could be readily expanded in 
consideration of combinational therapies targeting other tumor RTKs, or even more 
broadly, to all HSP90 client proteins that are differentially overexpressed by tumor cells 
versus their normal cellular counterparts.  
 
A number of previous reports have detailed the important role mediated by HSP90 in 
intrinsic antigen presentation and induction of inflammatory immune responses 
[358,371], as well as, the contribution that this HSP plays in the cytosolic translocation of 
extracellular antigens in the cross-presentation of T cells by dendritic cells (DC) 
[359,360]. Therapeutic inhibition of HSP90 (using 2nd and 3rd generation inhibitors) has 
been suggested as an effective treatment option for autoimmune diseases, in order to 
dampen the activity of self-reactive T cells [362,386]. However, these same attractive 
attributes in the setting of autoimmunity would likely prove disastrous in the cancer-
bearing host, leading to rapid disease progression or recurrence.  
 
To address this theoretical concern, I first evaluated the impact of 17-DMAG on immune 
cell phenotype and function in vitro. I noted that 17-DMAG treatment can negatively 
affected DC phenotype and function (the ability of DC to stimulate allogenic T cells) in a 
dose-, as well as, treatment duration-dependent fashion. When we looked at the effect of 
17-DMAG on CD8+ T cell activation, a longer duration of treatment was required in 
order to discern any effect on these responder cells. In contrast, CD4+ T cells appeared 
resistant to the action of the HSP90 inhibitor. The apparent inhibition of immune cell 
function could be due to the differential toxicity of this drug, leading to biased cell death 
profiles, or to the deregulation of important intrinsic signaling pathways affecting 
DC/CD8+ T cells, but not CD4+ T cells. Indeed, NFKB, a master transcription factor 
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playing a role in transcription of inflammatory mediators and DC maturation, is an 
HSP90 client, as is Zap70 and several other T cell signaling molecules [358,359]. 
Overall, my murine in vitro data were consistent with other reports suggesting that 17-
DMAG could have adverse (functional) effects on cells of the immune system, which 
was a source of major concern for me, as I planned the in vivo studies, leading me to 
stress an analysis of changes in the “immunophenotype” of the tumor and lymphoid 
organ microenvironments as a consequence of mice being treated with 17-DMAG.  
 
In my preliminary in vivo experiments, I was careful to evaluate both the dose- and  
schedule-dependency of 17-DMAG administration on the tumor immunophenotype. I 
found that treatment of tumor-bearing animals with 17-DMAG for 5 days at a dose of 15 
mg/Kg was optimal to enhance EphA2+ tumor cell recognition by EphA2-specific CD8+ 
T effector cells. Treatment at lower doses/times led to minimal impact on EphA2-specific 
T cell recognition of tumor cells, while treatment of animals for more than 5 days, or at 
doses higher than 15 mg/Kg, resulted in a reduction in the positive treatment effects 
observed using the 15 mg/Kg x 5 day protocol.  This was clearly reflected in the tumor 
growth curves, since mice treated with 15 mg/Kg for 5 days show stabilization of tumor 
growth, while provision of higher doses of drug/longer treatment duration did not 
statistically improve suppression in tumor growth.  When I looked at the effect of 17-
DMAG on the immune cell composition in the tumors, I saw that 17-DMAG treatment 
for up to 5 days caused an increase infiltration of CD4+, CD8+ T cells and DCs, and 
decreased incidence of Tregs and MDSCs in the TME. However, treatment for more than 
5 days reversed this phenomenon. Hence, it may be very possible that as observed in 
vitro, prolonged treatment fro more than 5 days with 17-DMAG may indeed be toxic to T 
cells and DCs, leading to their reduced prevalence in tumors and lymphoid organs. Tregs 
and MDSCs could be more refractory to the effects of 17-DMAG, and it possible that 
continued treatment of tumor-bearing animals with 17-DMAG for periods longer than 10 
days might eventually have a negative effect on such regulatory cell populations as well. 
While such future studies are warranted, my current data suggest that a 
biologic/immunologic “prozone” exists for 17-DMAG-based therapy, with an optima in 
the mouse of 5 days at 15 mg/Kg/day. 
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In this regard, I have just begun to scratch the surface of the possible underlying 
mechanisms of action linked to the increase in inflammatory cells in the TME and 
decreased incidence of Tregs and MDSCs. The mRNA transcription profiles from 17-
DMAG treated versus untreated mice suggests that 17-DMAG treatment causes an acute 
increase in type-1 immune response genes, and a decrease in non-type 1-associated gene 
transcripts. In addition, 17-DMAG caused a decrease in MDSC-function associated genes 
like arginase1, IDO and iNOS, which could be most readily explained by the decrease in 
MDSC recruiting molecules like CXCR4, CXCL12, S100A8 and S100A9 in the TME 
[288]. I also observed an increase in type-1 T cell chemokine/chemokine receptors like 
CXCR3, and its ligands, CXCL9 and CXCL10. At the protein level, I noted that 17-
DMAG treatment caused an increase in expression of CXCL10 and VCAM-1 by the 
tumor and its associated stroma and blood vessels, respectively . In addition, high levels 
of pSTAT3 in the progressor TME were replaced by (type-1-associated) pSTAT1 after 
administration of 17-DMAG for up to 5 days in vivo. 
 
A particularly interesting piece of this puzzle may relate to my observations pertaining to 
decreased levels of HIF1a and HIF2a transcripts expression in the TME after treatment 
with 17-DMAG. HIFs are HSP90 client proteins, and therefore when HSP90 is inhibited, 
HIF levels are reduced post-translationally [387]. Since STAT3 is a transcriptional 
regulator of HIFs, drug-induced reduction in pSTAT3 may also reduce HIF transcription 
in vivo. HIFs protect tumor cells by upregulating pro-survival pathways in tumor cells 
and cancer stem cells under low-oxygen conditions [388]. They also promote vascular 
endothelial growth factor (VEGF) in support of angiogenesis in the TME. In addition, 
HIFs may also promote a down-modulation in locoregional expression of adhesion 
molecule by tumor and tumor-associated stromal cells. Hence, perturbing HIF levels via 
the use of 17-DMAG may lead to increased expression of (type-1 T cell recruiting) 
VCAM-1 and CXCL9/10, and decreased angiogenesis and regulatory cell footprint in the 
TME [389].  
 
Interestingly the anti-angiogenic tyrosine kinase inhibitors (TKIs) sunitinib, axitinib and 
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dasatinib appear to modify the TME in vivo in an operationally similar manner [390,391], 
Lowe et al., unpublished data. Even though, I did not look at the effects of 17-DMAG on 
tumor-associated pericytes and cancer stem cells, given the known impact of hypoxia on 
these indices, it is predicted that 17-DMAG affects these cell populations, thereby 
sensitizing the TME and reconditioning it to more conducive to effector T cell 
recruitment and sustenance. Further studies will need to be performed to delineate causal 
underlying mechanisms of action associated with 17-DMAG anti-tumor efficacy and the 
development of protective and durable anti-tumor immunity. Figure 22 details our 
understanding of the biologic alterations in the TME following 17-DMAG treatment.  
 
Since 17-DMAG treatment was for a short window of time, we expected the results to be 
short-lived and reversible once treatment was discontinued. While this was true in the 
case of tumor EphA2 degradation and the enhanced recognition of tumors by EphA2-
specific T cells, we observed prolonged beneficial effects with regards to infiltration of 
inflammatory cells into the TME. This may relate to differential drug thresholds required 
to impact each of these biologic indices or the comparative ability of a given HSP90 
client protein that is key in the biologic cascade supporting the endpoint index. Given my 
data, however, it is suggested that one may want to administer 17-DMAG as a “pulse 
therapy” in order to periodically and reiteratively activate the recruitment and function of 
protective immunity within the TME to optimized therapeutic benefit. Such effects may 
be further accentuated by increasing the number of circulating, “recruitable” anti-tumor T 









In this context, I evaluated the efficacy of 17-DMAG in 4 different combinational therapy 
settings – i) with intratumoral IL12 gene therapy; ii) with DC-based EphA2 vaccines; iii) 
with adoptive transfer of EphA2 specific T cells provided wither intra-tumorally (i.t.) or  
iv) intra-venously (i.v.). In all cases, the combination therapy exhibited superior anti-
tumor efficacy when compared to the component, single modalities, with the best 
therapies leading to the greatest infiltration of specific CD8+ T cells into the TME. 
Inhibition of HSP90 by 17-DMAG causes a) increased presentation of RTK-derived 
peptides on tumor MHC class I molecules  causing increased recognition of the tumor by 
specific Tc1 b) 17-DMAG mediated vascular normalization, decreased hypoxia and 
increased VCAM1/CXCR3 ligand expression leads to increased infiltration of protective 
Tc1 and DCs which in turn leads to increased cross-priming, prolonged sustenance of 
Tc1 and generation of a memory response.  
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In my hands, 17-DMAG administration combined with DC/EphA2 peptide-based 
vaccination in the EphA2+ tumor setting (i.e. MCA205) was arguably the most effective 
combinational approach. Treatment resulted in the complete regression of tumors and  
generation of durable memory immune responses. Adoptive transfer of EphA2-specific T 
cells (i.t.) in combination with 17-DMAG also demonstrated potent anti-tumor effects, 
leading to extensive tumor necrosis and a complete liquefaction of the tumor in 
association with hemorrhaging in EphA2+ tumor blood vessels. 17-DMAG treatment did 
not hinder the trafficking of primed T cells to the tumor, as evidenced by the massive 
tumor necrosis observed in combinational therapy experiments with i.v. transfer of 
EphA2-specific T cells. This remarkable necrosis was specific for mice receiving the 
combinational therapy with EphA2-specific T cells (and not observed in DC-based 
vaccine approaches, which also involves elicitation of EphA2-specific T cell responses). 
This could be due to the higher functional avidity of (adoptively-transferred) EphA2-
specific T cells generated by immunizing EphA2-/- mice, as opposed to comparatively 
low-to-moderate avidity anti-EphA2 T cells developed as a consequence of DC-based 
vaccines.  
 
One of the biggest concerns with immunotherapy targeting tumor-associated antigens is 
the imminent threat of adverse autoimmune reactions against normal organs and tissues. 
In our case, EphA2 is expressed by a number of normal organs like kidney, intestine, 
lungs etc. In addition, HSP90 is a ubiquitous protein present in all cells. So combining 
HSP90 inhibition with EphA2-specific immunotherapy could potentially cause 
autoimmune reactions against other EphA2-positive organs. I did not observe any 
changes in the gross morphology of mouse organs like kidneys and lungs, nor did I note 
that treated animals underwent changes in their weight or behavior. Importantly, I was 
able to demonstrate that my combined therapy even worked in cases where EphA2neg 
tumors were being treated, based on anti-EphA2 recognition of tumor-associated EphA2+ 
vascular endothelial cells (VEC). These same protective T cells failed to recognize VEC 
isolated from the kidneys of these same mice receiving combinational therapy, which 
may directly relate to the higher EphA2 transcript/protein levels I observed for tumor-
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versus-normal VEC, etc.. Overall, I did not observe tangible evidence of off-target, 
autoimmune sequelae in mice treated with 17-DMAG combination therapy approaches, 
suggesting that these may be seriously considered for translation into the clinic. 
 
In all, my studies provide a proof-of-principle for the performance of analogous studies 
combining HSP90 with the immunotargeting of alternate HSP90 client proteins 
overexpressed by tumor cells or tumor-associated stromal cells. If a specific client protein 
can be demonstrated to undergo degradation via the proteasome, there is a good chance 
that HSP90 administration can promote its delivery into MHC class I complexes allowing 
for improved recognition by client protein-specific CD8+ T cells. My preliminary data 
suggests this will likely be the case for the combination therapeutic targeting of tumor-
associated antigens such as EGFR, Her2/neu, VEGFR1 and PDGFRβ. Considering the 
wide range of HSP90 clients in the tumors mediating a diverse range of functions, 
combinational immunotherapy with HSP90 treatment could be applied to a wide range of 
tumors and their associated vasculature (primary or metastatic), thus making this 
therapeutic approach extremely versatile and effective. Furthermore targeted 
combinational therapeutics might be accentuated by the inclusion of antibodies specific 
for cell-surface tumor-associated HSP90 client proteins (i.e. RTKs, among others) given 
the ability of these agents to selectively promote their internalization/ degradation and 
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